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SUMMARY 
 
The human intestinal fatty acid binding protein (FABP2) is a cytosolic 15 kDa protein 
and is involved in resorption of long-chain fatty acids. Phenotyping of FABP2 knock-
out mice and association analysis of promoter haplotypes revealed FABP2 as a 
susceptibility gene for insulin resistance and related traits. Relevant FABP2 promoter 
polymorphisms -80Del>T, -136AGTAG>Del, -168AAG>T, -260G>A, -471G>A, and  
-778G>T result in two haplotypes A and B. Haplotype B possesses 2-3 fold lower 
transcriptional activity than A. The aim of this work was to investigate the general and 
haplotype-specific transcriptional regulation of the human FABP2 promoter. For this 
purpose, reporter gene assays in human colonic carcinoma Caco-2, cervix carcinoma 
Hela and hepatoma Huh7 cells, site-directed mutagenesis, electrophoretic mobility 
shift assays and supershift-assays were used. The specific binding of hepatic nuclear 
factor 1 alpha (HNF-1α), HNF-4α and GATA factors to FABP2 promoter haplotypes 
was investigated. The trans-activation of the promoter by these major intestinally 
expressed transcription factors was also studied. The factors are involved in 
differentiation and nutrient dependent gene regulation. 
 
In electromobility shift and supershift assays the presence of two overlapping HNF-1 
binding sites within the FABP2 promoter regions -185/-165 and -169/-149 was 
shown. Reporter gene analysis in Caco-2 and Hela cells demonstrated that HNF-1α 
activates an 836 bp FABP2 promoter construct by 3.5 and 20-fold, respectively. This 
induction is identical between FABP2 promoter haplotypes. Mutational analysis of 
HNF-1 element -185/-165 resulted in about 50 % reduction of basal activity of the 
FABP2 promoter construct in Caco-2 cells. Disruption of the –169/-149 element had 
marginal effect. Co-transfection experiments in Hela cells with HNF-1α revealed 
similar reduction in activity of FABP2 promoter mutants. Further electromobility shift 
assays demonstrated that HNF-4α binds at position -336/-324 of the FABP2 
promoter. Mutation of this HNF-4 binding site abolished the luciferase reporter activity 
of FABP2 in postconfluent Caco-2 cells. In Hela cells, this mutation reduced the 
activation of the FABP2 promoter by HNF-4α by about 50 %. Thus, the binding 
element at position -336/-324 essentially determines the transcriptional activity of the 
promoter. This series of experiments demonstrates that FABP2 is strongly regulated 
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by the transcriptional factor HNF-1α and HNF-4α via identified functional recognition 
elements.  
 
In order to identify the causative polymorphism(s) for different activities of FABP2 
promoter haplotypes, reporter gene assays with a series of chimeric FABP2 promoter 
constructs were performed in Caco-2 cells. Data show that polymorphism -80Del>T, 
together with -136AGTAG>Del and -168AAG>T, essentially determines different 
activities of FABP2 promoter haplotypes. In accordance, in electrophoretic mobility 
shift assays transcriptional factors GATA-5 and -6 bind with higher binding affinities 
to the FABP2 promoter region containing the -80A allele compared to B. As 
functional consequence, haplotype A is twice as much activated by GATA factors 
than haplotype B in Huh7 cells. Additionally, a construct bearing the -80B allele in the 
background of haplotype A reversed the activity from A to B. Thus, the GATA 
mediated differential activation of FABP2 haplotypes depends on polymorphism  
-80Del>T. 
 
In conclusion, the data suggest a major role of transcriptional factors HNF-1α and 
HNF-4α in the control of FABP2 expression in intestine via a functional HNF-1 
recognition element within FABP2 promoter region -185/-165 and a HNF-4 element 
at position -336/-324. This seems to be of importance in the control of FABP2 
expression by differentiation and nutrients, e.g. dietary lipids. The different activities 
of FABP2 promoter haplotypes are essentially determined by GATA factors and are 
mediated by differential GATA binding to the polymorphic promoter region -80Del>T. 
Taken together, the work provides insights into the molecular basis of the general 
and variant specific transcriptional regulation of the diabetes type 2 associated 
human FABP2 gene. 
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ZUSAMMENFASSUNG 
 
Das humane intestinale Fettsäure-bindende Protein (FABP2) ist ein cytosolisches 15 
kDa Protein. Es ist an der Resorption von langkettigen Fettsäuren beteiligt. Die 
Phänotypisierung von FABP2 knock-out Mäusen und Assoziationsstudien mit 
beschriebenen Promotorhaplotypen zeigten, dass FABP2 ein Kandidatengen für 
Insulinresistenz und verwandte Krankheitsmerkmale ist. Die relevanten FABP2 
Promotorpolymorphismen -80Del>T, -136AGTAG>Del, -168AAG>T, -260G>A, 
-471G>A und -778G>T resultieren in zwei Haplotypen A und B. Haplotyp B weist eine 
zwei- bis dreifach niedrigere transkriptionelle Aktivität als A auf. In dieser Arbeit 
wurde die generelle und Haplotyp-spezifische transkriptionelle Regulation des 
humanen FABP2 Promotors untersucht. Hierzu wurden Reportergenanalysen in 
humanen Kolonkarzinomzellen Caco-2, Cervixkarzinomzellen Hela und 
Hepatomzellen Huh7, zielgerichtete Mutagenese und Gel-Retardations-Analysen 
angewendet. Desweiteren wurde die spezifische Bindung von Hepatozyten 
Nukleärem Faktor 1 alpha (HNF-1α), HNF-4α und GATA Faktoren an die FABP2 
Promotor Haplotypen analysiert. Außerdem wurde die Aktivierung des Promotors 
durch diese Transkriptionsfaktoren untersucht. Die Faktoren werden im Dünndarm 
exprimiert und sind an der differenzierungs- und nahrungsabhängigen Genregulation 
beteiligt.  
 
In Gel-Retardations-Analysen wurden zwei überlappende HNF-1 Bindungsstellen 
innerhalb der FABP2 Promotor Regionen -185/-165 und -169/-149 nachgewiesen. 
Reportergenanalysen in Caco-2 und Hela Zellen zeigten, dass HNF-1α ein 836 bp 
FABP2 Promotor-Reporter-Konstrukt 3.5- bzw. 20-fach aktiviert. Diese Aktivierung ist 
unabhängig von dem FABP2 Promotor Haplotyp. Eine Mutationsanalyse des HNF-1 
Elements -185/-165 führte zu einer Erniedrigung der Basalaktivität des FABP2 
Promotorkonstruktes in Caco-2 Zellen um etwa 50 %. Die Mutation des –169/-149 
Elements hatte keine relevante Auswirkung auf die Promotoraktivität. Co-
Transfektions-Experimente in Hela Zellen mit HNF-1α zeigten ähnliche Effekte auf 
die Aktivität der FABP2 Promotor Mutanten. Weitere Gel-Retardations-Analysen 
belegen, dass HNF-4α an Position -336/-324 des FABP2 Promotors bindet. Die 
Mutation dieser HNF-4α Bindungsstelle führte zu einer vollständigen Inaktivierung 
der FABP2 Promotor-Reporter Aktivität in postkonfluenten Caco-2 Zellen. In Hela 
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Zellen führte diese Mutation zur Erniedrigung der HNF-4α-induzierten Aktivierung 
des FABP2 Promotors um etwa 50 %. Somit wird die transkriptionelle Aktivität des 
FABP2 Promotors durch das identifizierte HNF-4 Bindungselement -336/-324 
erheblich beeinflusst. Die Daten zeigen insgesamt, dass der FABP2 Promotor 
maßgeblich durch die identifizierten funktionellen HNF1 und HNF4 
Erkennungssequenzen reguliert wird.  
 
Um die ursächlichen Polymorphismen für die unterschiedlichen Aktivitäten der 
FABP2 Promotor Haplotypen zu identifizieren, wurden Analysen mit einer Vielzahl 
von chimären FABP2 Promoter-Reporter-Konstrukten in Caco-2 Zellen durchgeführt. 
Die Daten zeigen, dass hauptsächlich der Polymorphismus -80Del>T, in Kombination 
mit -136AGTAG>Del und -168AAG>T, die unterschiedlichen Aktivitäten der FABP2 
Promotor-Haplotypen verursacht. In Übereinstimmung mit diesen Befunden zeigten 
Gel-Retardationsanalysen, dass die Transkriptionsfaktoren GATA-5 und -6 mit 
höheren Affinitäten an diejenige FABP2 Promotorregion binden, die das -80A Allel 
enthält. In Übereinstimmung mit diesem Ergebnis wurde in Huh7 Zellen aufgezeigt, 
dass die GATA Faktoren den FABP2 Promoter Haplotyp A doppelt so stark aktivieren 
wie Haplotype B. Weiterhin wurde eine FABP2 Promotormutante vom Haplotyp A 
hergestellt, die das -80B Allel enthält. Die GATA-5 induzierte Aktivität dieser Mutante 
ist nahezu identisch mit der Aktivität des Haplotyps B. Somit wird die GATA 
vermittelte differentielle Aktivierung der FABP2 Haplotypen vom Polymorphismus -
80Del>T verursacht. 
 
Insgesamt zeigt die Untersuchung, dass die Transkriptionsfaktoren HNF-1α und 
HNF-4α maßgeblich die Aktivität des FABP2 Promoters bestimmen. Dieser Effekt 
wird durch zwei funktionelle Bindungsstellen vermittelt, die sich im FABP2 Promoter 
in Position -185/-165 und -336/-324 befinden. Dieser Befund ist vermutlich für die 
Kontrolle der FABP2 Expression durch Differenzierung und Nährstoffe, wie zum 
Beispiel Nahrungsfette, bedeutsam. Die unterschiedlichen Aktivitäten der FABP2 
Promotor Haplotypen werden im Wesentlichen durch GATA Faktoren und den 
FAPB2 Promotor Polymorphismus 80Del>T bestimmt. Somit liefert diese Arbeit 
insgesamt Erkenntnisse zur molekularen Basis der generellen und Varianten-
spezifischen transkriptionellen Regulation des Diabetes Typ 2 assoziierten humanen 
FABP2 Gens. 
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GENERAL INTRODUCTION 
 
Fatty acid binding proteins (FABPs) are small (14-15 kDa) cytosolic proteins and 
were first described by Ockner et al. (1). The FABP family belongs together with the 
lipocalin family to the calycin superfamily, which functions in binding of small 
hydrophobic molecules. FABPs are conserved troughout the animal kingdom in 
vertebrates and invertebrates (2), although invertebrate FABPs do not have 
pronounced sequence motif analogies with vertebrate FABPs (3). In vertebrates, the 
family comprises 9 members: liver (FABP1), intestinal (FABP2), heart/muscle 
(FABP3), adipocyte (FABP4), epidermal (FABP5), ileal (FABP6), brain (FABP7), 
myelin P2 (MP2, FABP8) and testis FABP (FABP9) (4). The names were given 
according to the tissue, where a FABP was first discovered or is predominantly 
expressed.  
 
FABPs have a common tertiary structure that comprises 10 antiparallel β-strands 
forming a β-barrel, which are structured into two nearly orthogonal β-sheets, and two 
short anti-parallel α-helices that are located over one end of the barrel. This structural 
feature allows the formation of a binding pocket, which is partially filled with water. In 
the binding cavity polar amino acid residues interact with carboxylate groups of fatty 
acids by hydrogen bonding (5). Ligand binding properties differ between single 
FABPs. Besides saturated and unsaturated long-chain free fatty acids, specific 
FABPs are able to bind also other ligands, such as acyl-CoAs, bile salts, cholesterol, 
heme, eicosanoids or other hydrophobic molecules (4). 
 
The cellular functions of FABPs seem to be very versatile and may be specific for 
single FABPs in dependence on ligand binding and tissue distribution. FABPs 
influence metabolic pathways by binding and intracellular transport of fatty acids and 
other ligands, which are delivered to specific cellular compartments and enzymes. 
They mediate fatty acid signaling by transferring fatty acids to the nucleus as ligands 
for transcription factors, such as peroxisome proliferator-activated receptors 
(PPARs), and seem to be involved in regulation of growth and differentiation 
[reviewed in (6)]. More recently, an antioxidant function was shown for FABP1 (7, 8). 
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In intestine, the genes encoding FABP1, FABP2 and FABP6 are expressed. The 
expression patterns of these FABP members are overlapping, even if they show 
staggered expression maxima (9). Whereas FABP1 and FABP6 are also expressed 
in other tissues, the expression of FABP2 seems to be restricted to the intestine (6, 
10). At a cellular level, FABP2 is absent in crypt cells but is present at high levels in 
enterocytes of upper villus region (11, 12), where fat absorption takes place. It is 
proposed to be involved in intestinal fat absorption by cellular binding and trafficking 
of newly absorbed non-esterified long-chain fatty acids, which are finally assembled 
and secreted in triglyceride-rich chylomicrons (13-15).  
 
Results gained from in-vitro and in-vivo studies of FABP2 functions are not 
consistent. Overexpression of FABP2 in cell lines, that endogenously express FABP1 
and FABP2 (16-18), led to controversial results. Increased FABP2 expression in 
colonic carcinoma cell line Caco-2 led to reduction in fatty acid incorporation (19), 
increased cellular lipid content and reduced secretion (20). A similar approach in 
another intestinal epithelial cell line (HIEC) resulted in no alteration of fatty acid 
metabolism (17). Experimental data obtained in non-expressing FABP2 cells seem to 
be more homogenous. In undifferentiated stably FABP2 expressing ES cells, initial 
and maximal fatty acid uptake and cytoplasmatic diffusion was increased (21). 
Diffusion rate was also enhanced in FABP2 transfected L-cell fibroblasts (22). 
Furthermore, these L-cell fibroblasts showed increased initial fatty acid (oleic acid) 
esterification into triacylglycerols and elevated triacylglycerol and cholesteryl ester 
mass (23, 24). Analysis of a FABP2 knockout mouse did not strengthen the 
hypothesis that FABP2 is essential for intestinal fat absorption. Mal-absorption of 
fatty acids was not observed (25). Functional redundancies of FABPs may explain 
the difficulties to study the functions of a single FABP in Caco-2 cells or knock-out 
mice. 
 
Functional studies dealing with the FABP2 exon 2 polymorphism G>A (rs1799883) 
further support the hypothesis that FABP2 is involved in fat absorption. This 
polymorphism results in an amino acid exchange of Ala to Thr at codon 54 and 
causes higher in-vitro binding affinity of long-chain fatty acids (26). Transfection of 
both wild type and variant FABP2 in Caco-2 cells increased cellular fatty acid 
transport and triglyceride secretion (15). And intriguingly, in intestinal explants of 
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homozygous carriers of Ala or Thr-encoding alleles the secretion of newly esterified 
triglycerides and chylomicrons was higher in carriers of Thr-encoding allele (14).  
 
Although the function of FABP2 is not perfectly understood so far, studies with 
FABP2 knock-out mice as well as association studies provide evidence that FABP2 is 
a susceptibility gene for diabetes type 2 and related traits. Male FABP2 knock-out 
mice showed key symptoms of the metabolic syndrome such as increased plasma 
levels of insulin and triglyceride, increased body weight, and changes in liver 
histology, possibly resulting from impaired lipid metabolism (25, 27). Studies with the 
exon FABP2 polymorphism revealed that the FABP2 Thr54 variant is associated with 
parameters of insulin resistance. This was shown in numerous studies with different 
human populations [reviewed in (28)]. More recently, also the FABP2 promoter 
haplotypes were associated with postprandial triglyceride levels (29) and BMI (30). 
Previous studies including the work presented in [1] revealed that the 5´ upstream 
promoter region of FABP2 contains insertion/deletion sites -80Del>T,  
-136AGTAG>Del, -168AAG>T and SNPs –260G>A, -471G>A and -778G>T, which 
are in complete linkage disequilibrium resulting in only two haplotypes A>B (29-31). 
The rare FABP2 promoter haplotype B showed almost 2-3 fold lower transcriptional 
activity than haplotype A in Caco-2 cells (30, 31). 
 
Since FABP2 is an important gene in regulation of lipid, insulin and glucose 
homeostasis and its expression level seems to be critical for the development of 
diabetes type 2, the understanding of transcriptional control of FABP2 is of specific 
importance. As demonstrated in cell culture as well as in animal models, FABP2 
expression is basically dependent on differentiation and developmental processes, 
whereby it is up-regulated along with differentiation of cells and tissues (11, 12, 16, 
18, 32, 33). FABP2 expression is modulated also by hormones, fatty acids and 
cytokines. It was increased, when Caco-2 cells were stimulated with hydrocortisone, 
insulin, leptin, butyric acid, oleic acid, phosphatidylcholine and the cytokine tumor 
necrosis factor-alpha (TNF-α) (19), and decreased when cells were incubated with 
epidermal growth factor (EGF) (34). The peptide tyrosine tyrosine (PYY), a gut 
hormone that is secreted in presence of luminal long-chain fatty acids, increased the 
FABP2 expression in small intestinal somatic cell hybrids (35, 36). 
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In rats and mice PPAR-alpha agonists increased FABP2 mRNA level (37). Also 
knock-out mice gave evidence for regulation of FABP2 by specific signalling 
molecules. In transforming growth factor β1 (TGFβ1) knock-out mice FABP2 was 
down-regulated (38). Maybe, GATA factors (39) are involved in this regulation. 
Interestingly, FABP2 was also down-regulated in Estrogen related receptor α (ERRα) 
knock-out mice (40), that may be a clue for gender specific differences in association 
studies. 
 
The regulation of rat and mouse FABP2 promoters has been studied to some extent. 
Cohn et al. shows binding of CCAAT enhancer binding protein (C/EBP) to a proximal 
promoter element in rat promoter (41). In another study, a direct activation of rat 
FABP2 promoter by the hepatocyte nuclear factor 4 (HNF-4) and the apolipoprotein 
A1 regulatory protein 1 (ARP-1) was demonstrated (38). Furthermore the TGFβ-
SMAD/GATA-4 signaling was shown to be involved in the up-regulation of mouse 
FABP2 promoter activity (29-31). Early FABP2 promoter studies in transgenic mice 
with FABP2 promoter-growth hormone reporter gene have identified promoter 
elements in rat FABP2 promoter that regulate FABP2 expression along duodenal-
colonic and crypt-villus axis within the gut epithelium (40). 
 
Previous investigations of human FABP2 promoter regulation concerned only basal 
activities of the two FABP2 promoter haplotypes (30, 31), that differ 2-3 fold in Caco-
2 cells. To gain more insights in this haplotype specific but also the general regulation 
of human FABP2 promoter, this work (4 publications or manuscripts)1 dealt with the 
following questions. 
 
1. Is the difference in the basal FABP2 promoter activities between the two 
haplotypes also present in postconfluent, semi-differentiated Caco-2 cells, that 
resemble rather the phenotype of enterocytes of small intestine.  
→ 1. Y. Li, E. Fisher, M. Klapper, H. Boeing, A. Pfeiffer, J. Hampe, S. 
Schreiber, B. Burwinkel, J. Schrezenmeir, F. Döring. Association between 
functional FABP2 promoter haplotype and type 2 diabetes. Hormone and 
Metabolic Research. 2006 May;38(5):300-7  
 
                                                 
1
 The work was carried out mainly in the Institute of Human Nutrition and Food Science, Department of 
Molecular Nutrition. 
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2. Which polymorphism(s) and transcription factor(s) are causative for these 
different activities. 
→ 1. Y. Li, E. Fisher, M. Klapper, H. Boeing, A. Pfeiffer, J. Hampe, S. 
Schreiber, B. Burwinkel, J. Schrezenmeir, F. Döring. Association between 
functional FABP2 promoter haplotype and type 2 diabetes. Hormone and 
Metabolic Research. 2006 May;38(5):300-7 
→ 2. M. Klapper, M. Böhme, I. Nitz and F. Döring. Type 2 diabetes 
associated Fatty Acid Binding Protein 2 promoter haplotypes are 
differentially regulated by GATA factors. Human Mutation. in press 
 
3. Which transcription factors mediate the general regulation of human FABP2 
expression. 
→ 2. M. Klapper, M. Böhme, I. Nitz and F. Döring. Type 2 diabetes 
associated Fatty Acid Binding Protein 2 promoter haplotypes are 
differentially regulated by GATA factors. Human Mutation. in press 
→ 3. M. Klapper, M. Böhme, I. Nitz and F. Döring. 2007. The human 
intestinal fatty acid binding protein (hFABP2) gene is regulated by HNF-4 
alpha. Biochemical and Biophysical Research Communication. 2007 Apr 
27;356(1):147-52.  
→ 4. M. Klapper, M. Böhme, I. Nitz and F. Döring. Transcriptional regulation 
of the Fatty Acid Binding Protein 2 (FABP2) gene by the hepatic nuclear 
factor 1 alpha (HNF-1α). submitted in Journal of Cellular Physiology 
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GENERAL DISCUSSION 
 
Previous studies regarding transcriptional regulation of human FABP2 were mainly 
done to characterize the basal activities of the two FABP2 promoter haplotypes (29-
31). The genetic variation in the FABP2 gene promoter is associated with 
postprandial triglyceride levels (29), body composition, lipid plasma levels (30) and 
diabetes (in [1], but not part of this dissertation). As shown previously (30, 31), the 
basal transcription of the rare FABP2 promoter haplotype B is about 2-3 fold lower 
than the common haplotype A. However, little effort was done to reveal regulation of 
the FABP2 promoter. The aim of the current work was to investigate the mechanisms 
of general and differential regulation of FABP2 promoter haplotypes. 
 
The differences in activities of 836 bp (upstream of translation start) FABP2 promoter 
reporter gene constructs were confirmed in this work in post-confluent Caco-2 cells 
[1]. In these partially differentiated cells, FABP2 mRNA and protein are expressed. 
Thus, the differentiated state of Caco-2 cells reflects the enterocytes phenotype in 
villus region of small intestine, where FABP2 is expressed. Therefore these data are 
more conferrable to in-vivo situation in small intestine. It should be noted, that there is 
no evidence for genotype specific expression of FABP2 in-vivo, since it is very 
difficult to obtain healthy tissue samples from the intestine. A first approach to reveal 
the causal polymorphisms for different transcriptional activities of FABP2 promoter 
haplotypes, promoter assays with shortened (388 bp upstream of translation start) 
promoter constructs, containing only the 4 proximal polymorphisms, were performed 
[1]. Promoter activities of these shortened constructs exhibit nearly the same 
differences in their activities as the long (836 bp) promoter version [1]. Therefore the 
differences in promoter activity seem to be determined by one or more of these 4 
proximal promoter polymorphisms. To study these polymorphisms in more detail 
reporter assays using chimeric FABP2 promoter constructs were performed [2]. 
These data show that difference in haplotype activities is essentially determined by 
the first three proximal FABP2 promoter polymorphisms, whereby -80Del>T has the 
greatest impact. Accordingly, clear differences in allele specific binding of nuclear 
proteins from post-confluent Caco-2 cells were observed for -80Del>T [2]. 
Furthermore, a higher binding capacity of GATA-5 and GATA-6 to the FABP2 
promoter region containing the -80A allele in comparison to the -80B allele was 
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demonstrated, that was reflected by higher induction of FABP2 promoter haplotype A 
compared to B. Therefore, different transcriptional activities of FABP2 promoter 
haplotypes are mainly caused by the -80Del>T polymorphism mediated by GATA 
factors. 
 
GATA-4, -5 and -6 are zinc finger-containing transcription factors and are present in 
various meso- and endodermal derived tissues such as intestine, heart, liver, lung 
and gonad. GATA-4, -5 and -6 are important transcriptional regulators of 
differentiation and embryonic development and tissue-specific gene expression (42-
45). These factors are also present in Caco-2 cells with GATA-6 as the predominant 
form (43, 46-48). A specific expression pattern of GATA-4, -5 and -6 was described in 
intestinal cells. GATA-6 is present at high levels in proliferating and less differentiated 
cells, whereas GATA-4 and -5 are strongly up-regulated along the crypt-villus-axis 
during cell differentiation (43). GATA factors are essential for general and tissue 
specific expression (38, 49). Interestingly, GATA factors bind to highly conserved 
elements in FABP2 promoters of mouse (mFABP2) and zebrafish (zFABP2) at 
regions corresponding to the human FABP2 promoter segment encompassing the  
-80Del>T polymorphism. These studies emphasize the crucial role of GATA in 
regulation of FABP2 in vertebrates. Interestingly, GATA-4 cooperates with Smad 
transcription factors, the downstream effectors of the TGFβ signalling pathway, to 
activate the mFABP2 promoter (38). TGFβ is a critical regulator of development and 
maintenance of intestinal epithelium (50). Taken together, GATA factors differentially 
induce the FABP2 promoter haplotypes mediated by the -80Del>T polymorphism 
encompassing promoter region. 
 
HNF-1α was identified in this work as an important transcriptional regulator of 
FABP2. It mediates 50 % of FABP2 promoter activity in Caco-2 cells. The HNF-1α 
induced FABP2 promoter activity in Hela cells is mainly dependent on the FABP2 
promoter region -185 to -165. Interestingly this region contains two HNF-1α binding 
sites, whereby only one site seems to be functional. The human FABP2 promoter 
segment -185 to -165 has no corresponding element in FABP2 mouse, rat or bovine 
promoter sequence at similar position but is conserved within a nearly conserved 
region in primates. This suggests a unique intestinal regulation of FABP2 by HNF-1α 
in primates. Although the identified HNF-1α sites are located within the -168AAG>T 
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polymorphic region, no haplotype specific activation of FABP2 was observed [4]. 
Further investigations demonstrated that HNF-4α is also a key regulator of FABP2 
transcription. It was shown, that HNF-4α binds at position –336 to -324 of the FABP2 
promoter. This binding essentially determines the transcriptional activity of the 
promoter. Together, these data emphasize the essential role of HNF-1α and HNF-4α 
as general activators of FABP2 promoter activity [3].  
 
Synergistic actions of transcription factors 
Taking into account that transcriptional regulation is not the result of binding of single 
transcription factors to isolated motifs, synergistic actions between the investigated 
and other intestinal expressed factors should be considered. Synergistic actions 
between transcription factors are mediated for example by physical interactions of 
factors and/or binding to neighbouring sites. GATA factors may differentially regulate 
FABP2 promoter haplotypes in synergistic action with HNF-1α, HNF-4α and CDX-2. 
Synergistic interactions between these factors are responsible for tissue-specific high 
expression of intestinal genes (51-56). This possible cooperative activation of FABP2 
promoters by GATA factors with HNF-1α and other factors very likely results in high 
expression of FABP2, whereby the difference in transcriptional activities of FABP2 
haplotypes may be essentially determined by GATA factors. Since GATA factors play 
a major role in differentiation processes of intestine and are supposed to be important 
for intestine-specific high expression (42-45), an in-vivo expression that is similar 
robustly regulated with respect to the differential regulation of FABP2 promoter 
haplotypes may be proposed. HNF-4α was previously described to synergistically 
interact with HNF-1α (57, 58) and other factors, such as Sp1 (59) or HNF-3 (60) to 
induce reporter activity of apoCIII, FABP1 and apoAI promoters, respectively. HNF-
4α binding sites were proven to be essential for functional synergism with these 
factors. Since the here investigated GATA factors, HNF-1α and HNF-4α may also 
function on FABP2 promoter in synergistic action, they may be in concerted action 
responsible for tissue-specific high expression of FABP2. 
 
Genotype interactions between genes 
FABP2 is a candidate gene for diabetes type 2 (non-insulin dependent diabetes 
mellitus, NIDDM) and related traits. The FABP2 T54 allele of exon 2 A54T 
polymorphism could be linked to insulin resistance in different populations (28). Also 
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FABP2 promoter haplotypes were associated with NIDDM [1], body weight (30) and 
triglyceride levels (29). Interestingly, GATA-4 cooperates with Smad transcription 
factors, the downstream effectors of the TGFβ signalling pathway, to activate the 
mouse FABP2 promoter (38). Notably, polymorphic sites in the TGFβ gene are 
associated with diabetes and obesity phenotypes, e.g. body composition, increased 
insulin and glucose levels (61, 62). Furthermore, also HNF-1α and HNF-4α are 
candidate genes for diabetes type 2. HNF-1α is discussed to be associated with late 
onset form of diabetes type 2 (63-65). The identified coding SNPs of HNF-1α I27L 
and A98V alter its transcriptional activity (64). Although there is no differential 
regulation of FABP2 promoter haplotypes by HNF-1α, the combination of particular 
FABP2 and HNF-1α genotypes in individuals may be of importance for differences in 
expression level of FABP2 in-vivo. In HNF-4α, 3 SNPs near the P1 promoter and 
exons 1-3 could be associated with diabetes type 2 in a finnish population (66). In 
conclusion, on basis of the here demonstrated functional interaction of FABP2 and 
GATA and very likely TGFβ, HNF-1α and HNF-4α it seems to be a powerful 
approach for genetic epidemiologists to study effects of genotype combinations of 
these genes on the development of NIDDM and other traits of the metabolic 
syndrome. 
 
Possible dietary regulation of FABP2 
An influence of dietary factors on HNF-1α and HNF-4α by modulating signalling 
pathways was provided by several observations and mechanisms. Firstly, HNF-1α is 
involved in the glucose-dependent transcriptional regulation of sucrose-isomaltase 
(67-69) and sodium-dependent glucose transporter (70). Secondly, expression and 
DNA binding of HNF-1α in livers of protein restricted rats were increased (71). 
Thirdly, glucose as well as fatty acids stimulated insulin secretion resulting in 
decreased activity of cAMP-dependent protein kinase A (PKA). Phosphorylation of 
HNF-4α by PKA results in decreased binding affinity to DNA (72). Fourthly, an 
increased ATP level, that reflects the energy status of a cell, inhibit 5´-AMP 
dependent kinase (AMPK) (73). AMPK was shown to suppress the expression of 
several transcription factors including HNF-1α and HNF-4α (74) and phosphorylates 
HNF-4α which leads to reduced protein stability, dimer formation and DNA binding 
(75). Expression and stability of HNF-1α and binding of HNF-1β to DNA, as 
previously shown with sucrose-isomaltase promoter, is also dependent on protein 
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phospatase 1a/2a activity (76). Together, diet induced changes in ratio of cellular 
protein kinase and phosphatase activity seem to regulate transcription factor 
activities, including HNFs. Intriguingly, HNF-4α, originally considered as orphan 
nuclear receptor, was previously shown to bind fatty acid acyl-CoA esters as ligands. 
These were able to modulate HNF-4α DNA binding activity in dependence on their 
chain length and saturation grade (77, 78). Interestingly, HNF-4α is involved in 
transcriptional regulation of ApoA-IV by lipid micelles, when micelles supplied to 
apical pole of Caco-2 cells.  
 
As shown recently, the peroxisome proliferator activated receptors (PPARs) activate 
FABP2 promoter (79), whereas sterol-regulatory binding protein (SREBP) decreases 
activity (data not shown). These factors are regulated by fatty acids. Interestingly, 
HNF-4 and PPARs are inversely regulated. Whereas HNF-4 is inhibited by 
polyunsaturated fatty acids (PUFAs) (77, 78), PPARs are activated by these ligands 
(80). SREBP 1a and 1c are negatively regulated at transcriptional as well as post-
translational, proteolytic processing level by PUFAs (81-83). Therefore, HNF-1α and 
HNF-4α in complex interplay with other transcription factors may be general 
mediators of nutritional signals and cellular energy status for transcriptional 
adaptations of FABP2 expression in enterocytes. Based on this hypothesis it also 
seems to be interesting to study the influence of FABP2 promoter haplotypes with 
respect to nutrients, such as fat intake in an epidemiological approach.  
 
Although the investigation of the general and promoter haplotype specific regulation 
is of interest and importance for knowledge about general regulatory mechanisms, 
the presented data are difficult to use for specific modulation of (genotype 
dependent) expression of FABP2. As discussed above, a possible dietary prevention 
could be mediated by several, partly opposing mechanisms. Because of potential 
imbalances of transcription factors and general artificial conditions in cell culture, 
investigation regarding nutrient dependent regulation of FABP2 promoter in Caco-2 
cells is of limited practical relevance. Furthermore, specific modulation of an isolated 
gene in complex transcriptional regulation processes is not feasible. It should also be 
considered, that transcriptional regulation is only one possible regulatory mechanism 
among many to modulate cellular protein level and activity. These posttranscriptional 
mechanisms include for example mRNA degradation, translational inhibition by non-
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coding and micro RNAs, protein phosphorylation or protein degradation. However, 
the implemented experimental system seems to be very powerful for future studies to 
investigate principles of nutrient dependent and variant specific transcriptional 
regulation of the diabetes type 2 associated human FABP2 gene.  
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Introduction
Fatty acid-binding proteins (FABP) represent a family of small
(14–15 kDa) cytosolic non-enzymatic proteins that play an es-
sential role in a) intracellular transport and metabolism of free
fatty acids, b) fatty acid-signaling pathways, and c) cell growth
and differentiation [1]. More than 20 different FABP genes are
expressed in a tissue-specific manner. The intestinal isoform
FABP-2 (I-FABP) has a high affinity for saturated and unsaturated
long-chain fatty acids, and participates in absorption of dietary
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Abstract
Fatty acid-binding protein 2 (FABP2) is a cytosolic protein
expressed exclusively in epithelial cells of the small intestine.
Some, albeit not conclusive, evidence indicates that the Thr-al-
lele of FABP2 Ala54Thr polymorphism is associated with type 2
diabetes. More recently, common FABP2 promoter polymorph-
isms have shown association with postprandial increase of tri-
glycerides, body composition and plasma lipid levels. Therefore,
we reasoned that variants in the FABP2 promoter may also pre-
dispose to type 2 diabetes mellitus. In our Caucasian study pop-
ulation, we found three SNPs and three insertion-deletion poly-
morphisms that are in complete linkage disequilibrium defining
promoter haplotype A and B within 1kb 5’ of the FABP2 initiation
codon. Haplotype calculations indicated that the FABP2 promo-
ter and Ala54Thr variants were strongly linked. Functional anal-
ysis of promoter fragments demonstrated that haplotype differ-
ence is caused by polymorphisms within 260 bp downstream of
the FABP2 initiation codon. Using a prospective case-control
study nested within the EPIC-Potsdam cohort of 192 incident
type 2 diabetes cases and 384 sex-/age-matched controls, male
subjects carrying the FABP2 haplotype B allele showed signifi-
cantly decreased risk of type 2 diabetes when adjusted for BMI
(OR = 0.50, 95% CI = 0.28–0.87, p < 0.05) and additional covari-
ates (OR = 0.42, 95% CI 0.22–0.81, p < 0.01). Further adjustment
for the Ala54Thr polymorphism revealed an OR of 0.18 (95% CI
0.06–0.49, p < 0.001). Similarly, Ala/Ala homozygote males car-
rying the promoter haplotype B had decreased risk (0.33, 0.11–
0.94, p < 0.05) of type 2 diabetes after stratification for the
Ala54Thr polymorphism. FABP2 promoter haplotypes or geno-
type combinations defined by the promoter and Ala54Thr poly-
morphism were not associated with BMI, body fat, leptin, HbA1c,
total cholesterol or HDL. In conclusion, our findings suggest that
the functional FABP2 promoter haplotypemay contribute to type
2 diabetes in a sex-specific manner.
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fatty acids [2]. Target inactivation of the FABP2 gene inmice leads
to hyperinsulinemia, suggesting that FABP2 has a central func-
tion in fat and hormone metabolism [3].
A significant linkage between the FABP2 locus and insulin resist-
ance has been identified in Pima Indians using a positional can-
didate gene approach [4]. Since FABP2 is a potent candidate gene
for hyperinsulinemia at this locus, a subsequent search for poly-
morphisms was initiated and an Ala54Thr (GfiA) substitution in
exon 2was identified [5]. The Thr54 allele could be linked to dys-
lipidemia and insulin resistance in different populations [6–11]
such as Mexican-Americans, Japanese and Caucasians. In con-
trast to that, an association between the Ala54Thr polymorphism
and a diabetes-related phenotype has not been found in other
populations [12,13]. In addition to the original study on Pima In-
dians, the associations between Ala54Thr polymorphism and
various quantitative traits related to insulin sensitivity have not
been not found in other studies [14,15]. More recently, poly-
morphisms in the promoter of FABP2 were investigated in three
studies [16–18]. FABP2 promoter polymorphisms are associated
with postprandial increase of triglycerides, body composition
and plasma lipid levels in non-diabetic subjects. Therefore, we
investigated whether FABP2 promoter polymorphisms are asso-
ciated with the risk of type 2 diabetes. A case-control study on
192 incident cases of type 2 diabetes and 384 control subjects
embedded in the EPIC-Potsdam study were employed for geno-
typing. Ala54Thr genotypes were taken into account while ana-
lyzing the effect of the promoter polymorphism. In addition, the
functionality of promoter polymorphisms was investigated by
reporter assays in FABP2-expressing Caco-2 cells.
Research Design and Methods
Subjects
Subjects were taken from the European Prospective Investigation
into Cancer and Nutrition (EPIC) Potsdam study, a population-
based, longitudinal study comprising a total of 27,548 partici-
pants from the area of Potsdam, Germany [19]. Baseline exami-
nations, including anthropometric measurements, blood sam-
pling, a self-administered food frequency questionnaire, and a
personal interview on lifestyle habits and medical history were
conducted between 1994 and 1998. During the first follow-up,
on average 2.3 years after recruitment, 192 incident cases of
type 2 diabetes mellitus were identified and confirmed by the
primary care physician [20]. Cases were matched with 2 control
subjects each by age and sex (n = 384). Gender distribution of
study participants was 59% male and 41% female subjects with
a mean age of 55.5 years (35 to 65 years). All study participants
had given informed consent and the genotype assessment was
agreed to by the local ethic committee. Body weight, height and
fat percent were determined at recruitment by means of stand-
ardized procedures as described previously [19]. BMI was esti-
mated as weight (kg) divided by height (m) squared. Detailed in-
formation on drug use was obtained at baseline and consisted of
all medications being taken during the previous four weeks on
the level of medication name. Sports activities were calculated
from hours/week in summer and winter.
Genotyping and sequencing of the FABP2 promoter
polymorphisms
At baseline, 30ml venous blood was taken from each study par-
ticipant and DNA was extracted by the spin-column method
(E.Z.N.A. Blood DNA Kit, PeqLab, Germany). Genotyping of inser-
tion/deletion promoter polymorphisms rs5861423 (- 136 bp up-
stream from the FABP2 initiation codon) and rs5861422 (- 80)
was performed by pyrosequencing using the PSQ 96 instrument
(Biotage AB, Uppsala) and PSQ 96 SNP reagents. Genotyping of
SNPs rs6857641 (- 260) and rs2282688 (- 471) was performed
with the TaqMan system (ABI, Foster City, CA, USA). Fluorescence
was measured using the ABI Prism 7900 HT sequence detection
system. Direct sequencing of genomic DNA samples from six un-
related subjects confirmed published SNPs [16–18] in the 5’ re-
gion of FABP2. A 838 bp fragment upstream from the FABP2
(M18079) start codon was PCR-amplified, inserted into pENTR/
D-TOPO vector (Invitrogen, Karlsruhe, Germany) and sequenced
by terminator cycle sequencing using Big Dye chemistry and ABI
3700 capillary DNA sequencer (Applied Biosystems, Foster City,
CA, USA). All PCR and sequencing primers were designed using
the OLIGO software and primers were purchased fromMWGBio-
tech AG (Ebersberg, Germany). Sequences of pyrosequencing pri-
mers, PCR primers as well as TaqMan assay primers and probes
are available on request.
FABP2 promoter SEAP reporter constructs
The secreted alkaline phosphatase (SEAP) reporter gene system
was used (BD Biosciences Clontech, Palo Alto, CA, USA). Cloning
procedures were performed using Gateway Technology (Invitro-
gen). 836 bp and 388 bp fragments upstream from initiation co-
don of FABP2 encompassing all six or the first four (– 80, – 136, –
168, – 260) promoter polymorphisms were amplified using Pfu-
Polymerase (Invitrogen) from genomic DNA of subjects homozy-
gous for promoter haplotype A or B. Amplified products were in-
serted into pENTR/ D-TOPO vector and sequenced. The resulting
plasmids pENTR-FABP2-Prom-attL contained attL-sites allowing
recombination reactionwith attR-sites. attR-sites (were inserted
into the SrfI blund-end site of the reporter plasmid pSEAP-Basic.
Subsequent recombination, catalyzed by LR Clonase, of the attL-
containing vector pENTr-FABP2-Prom-attL with attR-containing
vector pSEAP-Basic-attR resulted in final FABP2 promoter SEAP
reporter constructs. The pSEAP2-Basic plasmid lacking FABP2
promoter fragments served as a negative control vector.
Cell culture
CaCo-2 and Hela cells were provided by American Type Culture
Collection (ATCC, Rockville, MD) and were used between passage
70 and 110. Cells were cultured and passaged in MEM supple-
mented with 10% (HeLa) or 20% (Caco-2) fetal calf serum and 1
mM non-essential amino acids in a humidified incubator at 37 8C
under an atmosphere of 5% CO2. Cells were passaged at precon-
fluent densities using a solution containing 0.05% trypsin and 5
mM EDTA.
Reverse transcriptase (RT)-PCR and Western-blot analysis
For RT-PCR, total RNA was isolated from preconfluent and post-
confluent (day 1–6) Caco-2 cells with the RNeasyMini Kit (Quia-
gen, Germany) according to the manufacturer’s instructions. Oli-
gonucleotide primer pairs for FABP2 were designed based on
GenBank sequence accession number M18079. Sequences of pri-
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mers are available on request. For western-blotting, total protein
extracts from preconfluent and post-confluent (day 1–6) cells
were separated by SDS-PAGE (12–20%) using the XCell-Sure-
Lock Mini Gelsystem (Invitrogen, Germany), transferred to nitro-
cellulose, and probed with anti-FABP2 antibody (Santa Cruz Bio-
technology, USA).
Transfection and SEAP reporter assay
Cells were plated in 24-well plates and grown overnight to 40–
50% confluence. Transient transfection was performed using Fu-
Gene6 (Roche) according to the manufacturer’s protocol. Cells
were transfected with 0.192 g (Caco-2) or 0.384 g (HeLa) of
the reporter constructs or control plasmid pSEAP2-Basic.
0.008 g (Caco-2) or 0.016 g (HeLa) luciferase-containing plas-
mid pGL3-control (Promega) was co-transfected with the report-
er constructs to standardize for transfection efficiency. Caco-2
culture media were exchange 48 h after transfection. Cells were
grown another 72 h beforemediawere taken for the SEAP report-
er assay. Media from HeLa cells were taken for the SEAP assays
48 h after transfection. The SEAP reporter assay was carried out
with the Great EscAPe SEAP Chemiluminescence kit (Clontech)
on a white opaque 96-well flat-bottom microplate according to
the manufacturer’s protocol. SEAP activities were normalized by
luciferase activities measured from lysed cell pellets using com-
mercial Bright-Glo luciferase assay system (Promega). Activities
of the empty control vector pSEAP-Basis were subtracted from
SEAP reporter activities.
Statistical analysis
The study population was tested as a whole and cases/controls
individually for the distribution of genotypes according to the
Hardy-Weinberg-equilibrium with a c2 test (1 degree of free-
dom). Statistics were computed using SAS software 9.1 (SAS Insti-
tute, Cary, NC). Data on biochemical and genetic measurements
and measurements of body composition were missing in ten
type 2 diabetes mellitus and twelve control subjects; therefore,
analysis of covariance (ANCOVA) was performed on a final study
sample of 182 cases and 372 controls. Mean values were adjusted
for sex, age, bodymass index and waist-hip-ratio or in the case of
anthropometric variables for sex and age; p-values were correc-
ted for multiple comparisons. Associations between disease and
each SNP were assessed by conditional logistic regression analy-
sis. Significance level was set at p < 0.05 (1 degree of freedom).
Multivariate logistic regression analysiswas conducted adjusting
for body mass index (kg/m2), waist-hip ratio, sports activities (h/
week), total energy (kJ/d) and alcohol intake (g/d) and other non-
continuous covariates – presence of co-morbidities (hyperten-
sion or/and hyperlipidemia), smoking (current smoker, non-smo-
ker and former smoker), use of lipid-lowering drugs (statins, fi-
brates, CSE-inhibitors, others) and antihypertensives (ACE-inhi-
bitors, beta-blockers, Ca2+-channel blockers, others).
Results
Functional FABP2 promoter haplotypes
The 5’ upstream region of the FABP2 (M18079) initiation codon
contains three single nucleotide polymorphisms and three inser-
tion/deletion polymorphisms [16–18]. In our study, direct se-
quencing of the FABP2 5’ region as well as genotyping of poly-
morphisms confirmed previous findings in Caucasians [16–18]
that the six promoter polymorphisms are in complete linkage
disequilibrium (Fig. 2a). To verify and extend reported effects
[16–18] of FABP2 promoter polymorphisms, 836 bp and a 388
bp 5’ fragments of the FABP2 gene carrying either the A or B allele
were inserted into the SEAP reporter plasmid. The Caco-2 cell
Figure 2 Transcriptional activity in the reporter gene assay for various
FABP2 constructs. a Schematic presentation of reporter gene con-
structs used in transient transfection. The 5’ downstream region of
the FABP2 initiation codon contains six polymorphic sites at position
– 80 bp, – 136, – 168, – 260, – 471, and – 778. These sites are in com-
pete linkage disequilibrium and define FABP2 haplotype A and B. Posi-
tions of the polymorphisms were determined from the genomic FABP2
reference sequenceM18079 and based on numbering 5’ from the start
codon. b Caco-2 cells or HeLa were transiently transfected with FABP2-
SEAP reporter gene constructs haplotype A (A) and haplotype B (B).
836 bp and 388 bp FABP2 promoter fragments upstream from initia-
tion codon of FABP2, encompassing all six (838) or the first four (388)
promoter polymorphisms, was used. The resulting SEAP activity was
measured and normalized for transfection efficiency (Luciferase). Ac-
tivities of the empty control vector pSEAP-Basic were subtracted form
SEAP reporter activities. Results are reported in relation to the activity
of the 836 bp haplotype A. Data are given as mean  SEM from five ex-
periments; p = 0.0012 as determined by a paired t-test.
Fig. 1 FABP2 mRNA and protein expression in post-confluent Caco-2
cells. RNA and protein were isolated from preconfluent and post-con-
fluent (day 1–6) Caco-2 cells. FABP2 mRNA (a) was analyzed by RT-
PCR. Western-blot (b) was used for protein detection.
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line was selected for testing FABP2 promoter activities. As shown
in Fig.1, RT-PCR and Western-blot analysis revealed robust
FABP2 mRNA and protein expression in post-confluent CaCo-2
cells. Under these conditions, the 836 FABP2 haplotype B showed
40.2  7.3% (p = 0.0012) lower SEAP activity than the 836 FABP2
haplotype A (Fig. 2b). The short 388 FABP2 constructs produced
generally lower activities in comparison to the long constructs.
However, the short alleles containing polymorphisms – 80, –
136, – 168 and – 260 showed similar proportions in activity as
observed in the long promoter versions (Fig. 2b).
Association of the FABP2 polymorphisms with type 2 diabetes
To examine whether the functional FABP2 promoter variant con-
tributes to type 2 diabetes, we genotyped the polymorphisms in
a prospective nested case-control study taken from the EPIC-
Potsdam cohort. The baseline characteristics of 192 incident
type 2 diabetes subjects and 384 age and sex-matched controls
have already been described [20]. The resulting allele frequen-
cies (Table 1) were 55.8% for the FABP2 haplotype A and 44.2%
for the haplotype B in the overall study population. These fre-
quencies are similar to those previously reported in Caucasians
[16,17]. The genotype distribution was in compliance with the
Hardy-Weinberg equilibrium (p = 0.56). Inwomen, the frequency
of the FABP2 haplotype B was similar in cases (41.4%) and con-
trols (42.8%), whereas haplotype Bwasmore frequent in controls
(47.3%) than in type 2 diabetes subjects (41.9%) in the male sub-
group, but this difference did not reach significance (p = 0.2).
To evaluate the association between the FABP2 promoter poly-
morphisms and risk of type 2 diabetes, crude and adjusted odds
ratios (ORs) and their 95% CIs were calculated using conditional
logistic regression models (Table 2). Assuming co-dominant in-
heritance with the A/A-genotype as a reference group, the
FABP2 promoter polymorphism showed no significant associa-
tion with the risk of type 2 diabetes in the overall study popula-
tion in an unadjusted model (Table 2, model A). Since gender
may play a critical role in the effect of the FABP2 polymorphisms
[16,21], analysis was performed separately on males and fe-
males. No significant associations were found in females inde-
pendently of themodel used (Table 2). Inmales, the heterozygote
FABP2 promoter genotype A/B was significantly associated with
decreased risk (OR = 0.48, 95% CI = 0.27–0.87, p = 0.04) of type 2
diabetes when adjusted for BMI (model B). Comparable and sig-
nificant ORs were obtained for FABP2 genotypes A/B (0.45, 0.23–
0.9, p = 0.02) and B/B (0.41, 0.17–0.99, p = 0.05) when adjusted
for BMI, total energy intake, sport activities, lipid-lowering and
antihypertensive drug intake and concomitant diseases (model
C). Male subjects carrying the FABP2 haplotype B allele (geno-
type AB+BB) showed significantly decreased risk of type 2 dia-
betes when adjusted to BMI (OR = 0.50, 95% CI = 0.28–0.87,
p < 0.05) and additional covariates (0.42, 0.22–0.81, p < 0.01).
Haplotype analysis indicated that the FABP2 promoter and exon
2 (Ala54Thr) polymorphisms were not linked completely in our
Caucasian study populations (Table 3). Similar results were ob-
tained by Formanack et al. (2004). However, comparison of cal-
culated haplotypes revealed no significant differences between
cases and controls (Table 3). Therefore, we extended our associa-
tion study with respect to the Ala54Thr polymorphisms. When
analyses further adjusted for the exon 2 polymorphism, the pro-
moter AB (OR = 0.18, 0.06–0.49, p < 0.01) and BB (0.09, 0.02–
0.41, p < 0.01) genotypes were strongly associated with reduced
risk of diabetes inmales. Similar results were obtained after stra-
tification for the Ala54Thr polymorphism (Table 4). As shown in
Table 2 Association between FABP2 promoter genotypes and type 2 diabetes
Model Gender A/A A/B B/B A/B+B/B
OR OR (95% CI) OR (95% CI) OR (95% CI)
A all 1.00 0.84 (0.57–1.23) 0.81 (0.49–1.31) 0.83 (0.58–1.19)
men 1.00 0.59 (0.35–0.99)* 0.72 (0.38–1.37) 0.62 (0.38–1.01)
women 1.00 1.37 (0.76–2.48) 0.84 (0.39–1.84) 1.18 (0.68 2.04)
B all 1.00 0.72 (0.46–1.11) 0.51 (0.28–0.91)* 0.65 (0.43–0.99)*
men 1.00 0.48 (0.27–0.87)* 0.54 (0.26–1.15) 0.50 (0.28–0.87)*
women 1.00 1.33 (0.67–2.66) 0.38 (0.14–1.01) 0.93 (0.50–1.73)
C all 1.00 0.79 (0.50–1.26) 0.49 (0.26–0.94)* 0.69 (0.44–1.06)
men 1.00 0.45 (0.23–0.90)* 0.41 (0.17–0.99)* 0.42 (0.22–0.81)**
women 1.00 1.52 (0.72–3.21) 0.32 (0.10–1.03) 1.03 (0.52–2.03)
D all 1.00 0.56 (0.29–1.08) 0.32 (0.12–0.86)* 0.55 (0.29–1.06)
men 1.00 0.18 (0.06–0.49)** 0.09 (0.02–0.41)** 0.18 (0.06–0.49)+
women 1.00 2.51 (0.8–7.9) 0.81 (0.16–4.09) 2.11 (0.70–6.34)
*p < 0.05; **p < 0.01; +p < 0.001; Model A, crude; Model B, adjusted for BMI; Model C, adjusted for BMI, total energy (kJ/d) and alcohol intake (g/d), physical activ-
ity level, smoking, presence of hypertension or/and hyperlipidemia, use of lipid-lowering drugs and antihypertensives; Model D, adjusted for covariates as used in
model C and the FABP2 Ala54Thr SNP.
Table 1 Distribution of FABP2 promoter genotypes in incident
type 2 diabetes subjects and controls
Subjects AA AB BB B-allele
Cases (n = 188) 66 (35.1%) 87 (46.3%) 35 (18.6%) 41.8%
men (n = 112) 41 (36.6%) 48 (42.9%) 23 (20.5%) 41.9%
women (n = 76) 25 (32.9%) 39 (51.3%) 12 (15.8%) 41.4%
Controls (n = 376) 114 (30.3%) 182 (48.4%) 80 (21.3%) 45.5%
men (n = 224) 59 (26.3%) 118 (52.7%) 47 (21.0%) 47.3%
women (n = 152) 55 (36.2%) 64 (42.1%) 33 (21.7%) 42.8%
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the male subgroup, Ala/Ala homozygote males carrying promo-
ter haplotype B showed decreased risk (0.33, 0.11–0.94,
p < 0.05) of developing type 2 diabetes.
We also tested for associations between FABP2 promoter poly-
morphisms and common traits of the insulin resistance syn-
drome. As shown in Table 5, non-parametric covariance analysis
adjusted for age, physical activity level and smoking revealed no
significant differences among the three FABP2 promoter geno-
types and BMI, body fat percent, plasma levels of leptin, HbA1c,
total cholesterol or HDL-cholesterol. Genotype combinations de-
fined by the FABP2 promoter and exon 2 polymorphisms were
also not associated with these quantitative traits (Table 6)
Discussion
The present study provides the first evidence that the FABP2 pro-
moter polymorphism is associated with type 2 diabetes. Inter-
estingly, the association was found in men, but not women. In
non-diabetic control subjects, the FABP2 promoter polymorph-
ism was marginally associated with fat mass and triglycerides
in men only [16]. Sex-specific differences in triglyceride levels
were also found in an association study accounting for the
FABP2 Ala54Thr polymorphism [21], which is strongly linked to
the promoter polymorphisms. In agreement, FABP2 knockout
Table 5 ANCOVA on anthropometric and metabolic variables according to FABP2 promoter genotypes stratified by gender
A/A A/B B/B p** ‡ B allele p**
Men/Women (no.) 98/82 162/102 69/44 231/146
BMI1
Men 27.85 (27.13, 28.57) 28.32 (27.75, 28.89) 27.71 (26.84, 28.57) 0.8 28.14 (27.67, 28.61) 0.5
Women 27.47 (26.38, 28.55) 27.89 (26.91, 28.86) 28.63 (27.15, 30.12) 0.2 28.11 (27.3, 28.92) 0.4
Body fat (%) 1
Men 25.4 (24.3, 26.4) 26.1 (25.3, 27.0) 25.4 (24.2, 26.6) 1.0 25.91 (25.24, 26.59) 0.4
Women 37.0 (35.7, 38.2) 37.1 (35.9, 38.2) 37.3 (35.6, 39.0) 0.7 37.13 (36.2, 38.06) 0.8
Leptin (ng/ml)* 1
Men 5.1 (4.2, 6.2) 5.0 (4.3, 5.9) 3.9 (3.1, 4.9) 0.08 4.65 (4.08, 5.29) 0.5
Women 14.1 (12.0, 16.5) 16.2 (14.0, 18.7) 16.9 (13.5, 21.1) 0.2 16.38 (14.52, 18.48) 0.1
HbA1C (%)*
2
Men 5.41 (5.15, 5.68) 5.07 (4.88, 5.27) 5.23 (4.93, 5.54) 0.4 5.12 (4.96, 5.28) 0.06
Women 5.05 (4.85, 5.25) 4.94 (4.76, 5.11) 4.76 (4.51, 5.02) 0.09 4.88 (4.74, 5.03) 0.2
TC (mmol/l)* 3
Men 4.63 (4.45, 4.81) 4.74 (4.60, 4.89) 4.63 (4.41, 4.85) 0.9 4.71 (4.6, 4.84) 0.4
Women 5.04 (4.85, 5.24) 4.87 (4.70, 5.04) 4.90 (4.64, 5.17) 0.4 4.88 (4.74, 5.02) 0.2
HDL-C (mmol/l)* 3
Men 0.92 (0.89, 0.96) 0.89 (0.87, 0.92) 0.90 (0.85, 0.94) 0.3 0.90 (0.87, 0.92) 0.2
Women 1.10 (1.04, 1.15) 1.09 (1.05, 1.15) 1.11 (1.04, 1.20) 0.7 1.10 (1.06, 1.14) 0.9
Data expressed as means (95% confidence levels). * Loge transformed for statistical analysis, geometric means presented for transformed data;
1 adjusted for age,
physical activity level, and smoking; 2 adjusted for age, physical activity level, smoking, and BMI; 3 adjusted for age, physical activity level, smoking, BMI, lipid-low-
ering drug intake and hyperlipidemia; ** p-value refers to the difference of means between AA and BB (or AB+BB) diplotypes.
Table 4 Association of FABP2 promoter genotypes with type 2 diabetes in subjects homozygous for the Ala54 variant
FABP2 A/A
Ala/Ala
A/B
Ala/Ala
B/B
Ala/Ala
A/B+B/B
Ala/Ala
all Ca/Co (No.) 65/111 25/60 1/8 26/68
OR(95%CI)1 1.00 0.66 (0.30–1.46) 0.14 (0.01–1.82) 0.57 (0.27–1.21)
men Ca/Co (No.) 40/58 14/44 1/4 15/48
OR(95%CI)1 1.00 0.32 (0.11–0.94)* 0.47 (0.01–28.39) 0.33 (0.11–0.94)*
women Ca/Co (No.) 25/53 11/16 0/4 11/20
OR(95%CI)1 1.00 3.97 (0.63–24.95) – 1.29 (0.38–4.41)
* p < 0.05; 1 adjusted for BMI; Ca, cases; Co, controls.
Table 3 Calculated FABP2-promoter/Ala54Thr haplotype frequen-
cies
Haplotype All subjects Cases Controls p*
A Ala 0.549 0.574 0.538 0.3
A Thr 0.008 0.003 0.009 0.2
B Ala 0.145 0.131 0.152 0.3
B Thr 0.298 0.292 0.301 0.8
* c2-test for haplotype-trait association
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mouse showed sex-specific alterations in body weight with die-
tary fat content taken into account [3]. In a family study, a mater-
nal effect was observed at FABP2 [22]. In consideration of this
evidence, sex-specific effects of FABP2 polymorphisms on type
2 diabetes and related phenotypes seem apparent, although a
plausible mechanism has not been found so far. Maybe the
FABP2 expression is regulated by sex hormones that may modify
the different activities of FABP2 promoter haplotypes. This hy-
pothesis should be tested by using our FABP2 promoter con-
structs.
Functional analysis revealed a 2.5-fold decreased promoter ac-
tivity of FABP2 haplotype B in comparison to haplotype A in
post-confluent CaCo-2 cells. Previously, we obtained opposite re-
sults [18] in human embryonic intestinal cell line INT 407 (ATTC
CCL-006) with similar, but not identical promoter-reporter con-
structs. This line was originally thought to be derived from nor-
mal embryonic intestinal tissue [23], but subsequent analysis
[24,25] of isoenzymes, chromosomal markers and DNA finger-
printing revealed HeLa cell contamination. Therefore, the INT
407 cell line does not seem to be appropriate for promoter assays
and expression analysis, although we cannot exclude cell-specif-
ic differences in FABP2 promoter activity. Post-confluent CaCo-2
cells showed endogenous expression of FABP2 (Fig.1), which
makes this cell line particularly suitable for characterization of
the FABP2 promoter. The low activity of the promoter haplotype
B was also found by other groups [16,17]. We could also demon-
strate that four of six polymorphisms within 1kb 5’ of the FABP2
initiation codon are responsible for different haplotype activities.
The four variants comprise the region up to – 260 bp 5’ upstream
of the FABP2 initiation codon. This region contains several bind-
ing sites including PPAR/RXR. Evidence of the involvement of
PPARd# / RXRa in the regulation of FABP2 has been reported in
rats [26]. Assuming similar transcriptional regulation in humans,
the insertion/deletion variants could lead to altered binding affi-
nity of PPARd / RXRa to FABP2 promoter haplotypes. This poten-
tially results in different transcriptional activity, which is consis-
tent with our FABP2 promoter reporter assay. Of course, we do
not knowwhether the in vitro effect of the FABP2 promoter poly-
morphisms also occur in vivo and/or do affect heterozygote indi-
viduals. Comparing the relative gene expression levels from indi-
viduals with different FABP2 promoter genotypes may address
this problem.
Assuming altered FABP2 expression levels depending on promo-
ter genotypes in vivo, these may considerably affect fat metab-
olism and downstream effects on insulin resistance. Postprandial
concentrations of chylomicrones and triacylglycerol after inges-
tion of olive oil have been shown to be even higher in subjects
carrying the FABP2 Thr54 allele [27]. Because the “risk“ Thr54 al-
lele is strongly linked to the “prevention“ haplotype B promoter
allele, we propose independent effects of these functional var-
iants on the development of type 2 diabetes. Future studies in
larger populations will be necessary and more informative in re-
vealing the relative contribution of both polymorphisms in influ-
encing type 2 diabetes andmetabolic parameters. In our incident
case-control study, we found no evidence for any association be-
tween the FABP2 promoter polymorphism and parameters
linked to insulin resistance at baseline, although the variant was
associated with type 2 diabetes in men. Damcott et al. showed a
marginal association between promoter variants and body com-
position as well as plasma cholesterol in non-diabetic control
Table 6 ANCOVA on anthropometric andmetabolic variables according to FABP2 promoter genotypes stratified by gender in subjects homo-
zygous for the 54Ala variant
A/A+Ala/Ala A/B+Ala/Ala B/B+Ala/Ala p** ‡ B allele+Ala/Ala p**
Men/Women (no.) 96/80 57/26 5/4 62/30
BMI 1
Men 27.8 (27.1, 28.5) 28.6 (27.6, 29.5) 27.0 (23.7, 30.3) 0.6 28.4 (27.5, 29.4) 0.3
Women 27.5 (26.6, 28.5) 26.6 (24.9, 28.2) 27.1 (22.7, 31.5) 0.8 26.6 (25.04, 28.2) 0.3
Body fat (%) 1
Men 25.4 (24.3, 26.4) 26.6 (25.2, 28.0) 24.4 (19.7, 29.0) 0.7 26.4 (25.1, 27.8) 0.2
Women 37.0 (35.8, 38.3) 36.0 (33.7, 38.2) 36.7 (31.0, 42.5) 0.9 36.1 (34.0, 38.1) 0.4
Leptin (ng/ml) * 1
Men 5.14 (4.26, 6.21) 5.15 (4.04, 6.56) 2.17 (0.96, 4.87) 0.04 4.8 (3.8, 6.1) 0.7
Women 14.05 (11.97, 16.49) 13.76 (10.38, 18.23) 15.18 (7.30, 31.55) 0.8 13.93 (10.72, 18.11) 1.0
HbA1C (%) *
2
Men 5.40 (5.13, 5.68) 5.16 (4.83, 5.51) 5.10 (4.07, 6.33) 0.6 5.15 (4.84, 5.49) 0.3
Women 5.03 (4.81, 5.26) 5.10 (4.71, 5.52) 4.59 (3.74, 5.65) 0.4 5.03 (4.67, 5.42) 1.0
TC (mmol/l) * 3
Men 4.63 (4.43, 4.84) 4.79 (4.53, 5.08) 4.48 (3.70, 5.43) 0.7 4.77 (4.51, 5.04) 0.4
Women 5.10 (4.89, 5.28) 5.04 (4.71, 5.39) 5.40 (4.54, 6.43) 0.5 5.09 (4.78, 5.41) 1.0
HDL-C (mmol/l) * 3
Men 0.93 (0.89, 0.97) 0.91 (0.87, 0.97) 0.99 (0.82, 1.18) 0.5 0.92 (0.87, 0.97) 0.8
Women 1.11 (1.06, 1.17) 1.05 (0.96, 1.15) 1.17 (0.92, 1.49) 0.7 1.07 (0.98, 1.16) 0.4
Data expressed as means (95% confidence levels). * Loge transformed for statistical analysis, geometric means presented for transformed data;
1 adjusted for age,
physical activity level, and smoking; 2 adjusted for age, physical activity level, smoking, and BMI; 3 adjusted for age, physical activity level, smoking, BMI, lipid-low-
ering drug intake and hyperlipidemia; ** p-value refers to the difference of means between AA and BB (or AB+BB) diplotypes.
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subjects [16]. Overall, the physiological mechanism bywhich the
functional FABP2 promoter influences the risk of type 2 diabetes
remains obscure, most notably when sex-specific effects and
exon 2 polymorphism are taken into account. However, there is
some evidence, that FABP2 is not only expressed in enterocytes
but probably also in intestinal epithelial L-cells [28]. These cells
secrete the anti-diabetic hormones GLP1 and GLP 2 after fat in-
gestion. The expression level of FABP2 in L-cells could therefore
influences insulin sensitivity via fatty acid dependent GLP secre-
tion. This hypothesis should be tested by intervention studies
[29,30] with different FABP2 genotypes.
In this study, we found an association between the FABP2 pro-
moter haplotype B and reduced risk of type 2 diabetes in men.
The lower FABP2 promoter variant B expression level observed
could be functionally related to a short fragment of the haplo-
type B containing a PPARd / RXRa-binding site. This may alter
PPAR-dependent activation of the FABP2 promoter. There was
some evidence of intragenic interaction between the functional
FABP2 promoter and exon 2 Ala54Thr variants, but these results
need to be interpreted with caution and should be replicated in
future studies.
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Abstract 
The human intestinal fatty acid binding protein 2 (FABP2) mediates fat absorption by 
binding and intracellular trafficking of long-chain free fatty acids. Studies with knock-out 
mice and association analysis of polymorphisms revealed that FABP2 is a susceptibility gene 
for diabetes type 2 and related traits. Relevant FABP2 promoter polymorphisms c.-80_-
79insT (rs5861422), c.-136_-132delAGTAG (rs5861423), c.-168_-166delAAGinsT 
(rs1973598), c.-260G>A (rs6857641), c.-471G>A (rs2282688), c.-778G>T (rs10034579) 
result in two haplotypes A and B, whereby B possesses 2-3 fold lower transcriptional activity 
than A. We show in luciferase reporter gene assays by a series of chimeric FABP2 promoter 
constructs in intestinal Caco-2 cells that polymorphism c.-80_-79insT essentially determines 
different activities of FABP2 promoter. In accordance, in electrophoretic mobility shift assays 
transcriptional factors GATA-5 and -6 bind with higher binding affinities to the FABP2 
promoter region containing the -80A allele compared to B. As functional consequence, 
haplotype A is twice as much more activated by GATA factors than haplotype B in liver 
Huh7 cells. Additionally, a construct bearing the -80B allele in the background of haplotype 
A reversed the activity from A to B. Thus, the GATA mediated differential activation of 
FABP2 haplotypes depends on polymorphism c.-80_-79insT. This provides the molecular 
basis for the variant specific transcriptional regulation of the diabetes type 2 associated 
FABP2 gene. 
 
Keywords 
fatty acid binding protein 2, FABP2, Type 2 diabetes, promoter haplotypes, GATA factors  
Regulation of FABP2 haplotypes via GATA factors                                                        3  
  
Introduction 
 
Human fatty acid binding proteins (FABPs) represent a multigene family encoding ~15 kDa 
cytosolic proteins with nine members (Hertzel and Bernlohr, 2000) that are involved in 
central cellular processes. FABPs influence metabolic pathways by binding and intracellular 
transport of long-chain free fatty acids, which are delivered to specific cellular compartments 
and enzymes. They mediate fatty acid signaling by transferring fatty acids to the nucleus as 
ligands for transcription factors, such as peroxisome proliferator-activated receptors 
(PPARs),  and seem to be involved in regulation of growth and differentiation (Haunerland 
and Spener, 2004). 
 
The human intestinal fatty acid binding protein 2 gene (FABP2, OMIM accession number: 
134640; GenBank: NM_000134.2) is located on chromosome 4q28-q31, contains four exons 
and codes for a 15.1 kDa protein comprising 132 amino acid residues (Sweetser, et al., 1987). 
It is exclusively expressed in intestine with highest cellular concentrations in jejunum with 
falling levels to the proximal duodenum and colon (Cohn, et al., 1992; Sweetser, et al., 1988). 
FABP2 is up-regulated during development (Gordon, et al., 1985) and crypt-to-villus 
transition. Whereas FABP2 is absent in crypt cells, highest protein abundance is found in 
enterocytes of upper villus region (Shields, et al., 1986; Sweetser, et al., 1988), where fat 
absorption takes place. The particular function of FABP2 is still not fully elucidated. It is 
proposed to be involved in intestinal fat absorption by cellular binding and trafficking of 
newly absorbed non-esterified long-chain fatty acids, which are finally assembled and 
secreted in triglyceride-rich chylomicrons (Baier, et al., 1996; Levy, et al., 2001; Lowe, et al., 
1987).  
 
FABP2 is a candidate gene for diabetes type 2 (non-insulin dependent diabetes mellitus, 
NIDDM). According to this, a huge number of studies in different human populations 
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revealed associations between the minor allele of the FABP2 Ala54Thr polymorphism and 
risk parameters of insulin resistance (Weiss, et al., 2002). Functional studies showed 
increased binding affinity of the variant protein to long-chain fatty acids (Baier, et al., 1995). 
More recently, FABP2 promoter haplotypes were associated with postprandial triglyceride 
levels (Geschonke, et al., 2002), BMI (Damcott, et al., 2003) and type 2 diabetes (Li, et al., 
2006). The FABP2 coding and promoter polymorphisms are in strong or complete linkage 
disequilibrium (D´ 0.6-1.0) (Damcott, et al., 2003; Formanack and Baier, 2004; Li, et al., 
2006). In accordance with the association studies, male FABP2 knock-out mice showed key 
symptoms of the metabolic syndrome such as increased plasma levels of insulin and 
triglyceride, increased body weight, and changes in liver histology, maybe resulting from 
impaired lipid metabolism (Agellon, et al., 2006; Vassileva, et al., 2000). Therefore, the 
expression level of FABP2 seems to be critical for insulin sensitivity and triglyceride 
metabolism. 
 
Because FABP2 is a susceptibility gene for diabetes type 2 and related traits, its variant 
specific transcriptional regulation is of special interest. Previous studies (Damcott, et al., 
2003; Formanack and Baier, 2004; Li, et al., 2006) revealed that the 5´ upstream promoter 
region of FABP2 contains insertion/deletion sites c.-80_-79insT, c.-136_-132delAGTAG, c.-
168_-166delAAGinsT and SNPs c.-260G>A, c.-471G>A and c.-778G>T, which are in 
complete linkage disequilibrium resulting in only two haplotypes A>B. As demonstrated by 
us (Li, et al., 2006) and others (Damcott, et al., 2003; Formanack and Baier, 2004) the rare 
FABP2 promoter haplotype B showed almost 2-3 fold lower transcriptional activity than 
haplotype A in Caco-2 cells. In the present study we intended to reveal the causative 
polymorphism(s) and transcription factor(s) for these different activities. We show by a site-
directed mutagenesis approach, transfections and reporter assays of a series of FABP2 
promoter constructs in Caco-2 cells that polymorphism c.-80_-79insT had the greatest impact 
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in determining different activities of FABP2 promoter haplotypes. Based on electrophoretic 
mobility shift and transfection assays, the low activity of FABP2 promoter haplotype B is 
essentially determined by the -80B allele via GATA-5 and -6. Thus, we provide a molecular 
basis for the variant specific regulation of the type 2 diabetes associated FABP2 gene. 
 
Material and Methods 
 
Mutation Nomenclature – All positions of the polymorphisms are numbered relative to the A 
of the ATG translation initiation codon of the FABP2 reference sequence (GenBank: 
NM_000134.2). 
 
Cell culture - Hela and Caco-2 cells were purchased by German National Resource Centre for 
Biological Material (DSMZ, Braunschweig, Germany) and American Type Culture 
Collection (ATCC, Rockville, MD), respectively, and Huh7 cells were kindly provided by D. 
Hartwig (University Medical Center Schleswig-Holstein, Luebeck, Germany). Cells were 
maintained in MEM (Invitrogen, Carlsbad, CA), supplemented with 10% (Hela) and 20% 
fetal calf serum (Caco-2) (Invitrogen) and 1 mM non-essential amino acids (PAA, Cölbe, 
Germany) in a humidified incubator at 37°C under an atmosphere of 5% CO2. Huh7 cells 
were cultured in DMEM containing 4,5 g/L glucose and 10% fetal calf serum. Cells were 
passaged at preconfluent densities by use of 0.05% trypsin/5 mM EDTA (Biochrom AG, 
Berlin, Germany) solution every 2-3 days.  
FABP2 promoter luciferase constructs - The dual luciferase system was used (Promega, 
Madison, WI). Cloning procedures were performed using Gateway Technology (Invitrogen), 
described previously (Klapper, et al., 2007; Li, et al., 2006). 836 bp fragments upstream from 
initiation codon of the FABP2 promoter haplotypes A and B were subcloned by 
recombination with LR Clonase into attR-sites of pGL4.10[luc2] from vector pENTR-
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FABP2-Prom-attL resulting in final promoter reporter constructs pGL4.10[luc2]-FABP2(A) 
and pGL4.10[luc2]-FABP2(B). The empty pGL4.10[luc2] vector served as a negative 
control.  
 
Chimera constructs – Mutations in haplotype A (pGL4.10[luc2]-FABP2(A)) and haplotype B 
(pGL4.10[luc2]-FABP2(B)) containing promoter constructs were introduced to generate 
chimeras with single polymorphisms of haplotype B in the background of haplotype A (A-
xB) and vice versa (B-xA). Single polymorphism exchange chimera constructs are shortly 
named as follows: for exchange of polymorphism c.-80_-79insT of haplotype A (rs5861422): 
A-80B; for c.-136_-132delAGTAG (rs5861423): A-136B; for c.-168_-166delAAGinsT 
(rs1973598): A-168B, c.-260G>A (rs6857641): A-260B c.-471G>A (rs2282688): A-471B; 
c.-778G>T  (rs10034579): A-778B and vice versa. For introduction of exchanges at two 
polymorphic sites single mutant chimeras were used to generate double mutant chimeras. For 
instance, A-80B was used to introduce an additional exchange at polymorphism c.-136_-
132delAGTAG resulting in chimera A-80/136B. For generation of triple mutant chimeras 
double mutants were used. Introduction of mutations was performed using Quick ChangeTM 
in vitro mutagenesis Kit (Stratagene, La Jolla, CA). All primers were purchased from MWG 
Biotech AG (Ebersberg, Germany). Sequences of primers are available on request. 
Verification of constructs was performed by sequencing. 
 
Expression plasmids - Expression vectors for mouse GATA factors pcDNA-GATA-5 and 
pcDNA-GATA-6 were kindly provided by Dr. J. Philippe (University Hospital Geneva, 
Switzerland). 
Transient transfections and reporter assays - Transient transfections were performed with 
FuGene6 (Roche, Basel, Switzerland) according to the manufacturers instructions. 1 x 104 
Caco-2 cells were plated in 96-well plates. Cells were co-transfected with 47,5 ng 
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pGL4.10[luc2]-FABP2-Promoter constructs or pGL4.10[luc2] as negative control and 2,5 ng 
pGL4.74[hRluc/TK] vector encoding Renilla luciferase as internal control. Luciferase 
activities were measured 120 h after transfection by Dual-Luciferase® Reporter Assay 
System (Promega). 5 x 103 Huh7 cells were used for co-transfections with mouse GATA-5 
and -6. Cells were co-transfected with 30 ng pGL4.10[luc2]-FABP2-Promoter constructs or 
pGL4.10[luc2], 66 ng of the expression vectors pcDNA3-GATA-5, pcDNA3-GATA-6 or 66 
ng empty pcDNA3 vector and 3 ng pGL4.74[hRluc/TK] vector. Relative luciferase activities 
of negative control pGl4.10[luc2] were determined for each condition and were subtracted 
from corresponding activities for pGL4.10[luc2]-FABP2-Promoter constructs. Each 
experiment was repeated at least three times, and each sample was studied in triplicate. 
Hela cells were used for preparation of nuclear extracts containing GATA-5 and -6. 4 x 105 
cells were seeded in T25 flasks, transfected with 4 µg expression plasmid and extracts were 
prepared 48 h after transfection. 
 
Electrophoretic mobility shift assay (EMSA) - The biotinylated probe was prepared by end 
labeling oligonucleotides with biotin by the Biotin 3′ End DNA Labeling Kit (Pierce, 
Rockford, IL). Annealing of the unlabeled and labeled oligomers was done following the 
technical resource “Annealing complementary pairs of oligonucleotides” (Pierce). Nuclear 
extracts were prepared from Hela and postconfluent Caco-2 cells with the NE-PER Nuclear 
and Cytoplasmic Extraction Reagents Kit (Pierce). The EMSAs were performed with the 
LightShift Chemiluminescent EMSA Kit (Pierce) according to manufacturers instructions. 
The reaction mixture (20 µl) contained 1 mM Tris, 50 mM KCl, 1 mM DTT, 1 µg Poly (dI-
dC), 2,5 % Glycerol, 0,1 mM EDTA. The DNA-transcription factor complexes were resolved 
on a native 4 % Tris-borate-EDTA polyacrylamide gel in 0.5 x TBE buffer and transferred to 
a nylon membrane (Amersham Bioscience, Piscataway, NJ). Biotinylated DNA was detected 
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with streptavidin-horseradish peroxidase conjugate and chemiluminescent substrate Luminol 
using Chemiluminescence Nucleic Acid Detection Module.  
 
Statistical analyses - Statistical analyses were performed with GraphPad Prism 4 (Graphpad 
Software, Inc., San Diego, CA) using ANOVA and unpaired t-tests. The differences between 
haplotype A and B activities were tested with two-tailed t-tests. For comparison of chimera 
activities with haplotype A and B we used one-tailed t-tests because we hypothesized that 
activities of the chimera promoter constructs have to be below or above promoter activities of 
haplotype A and haplotype B, respectively. All values were expressed as means ± SEM. 
Significant differences were considered for P values less than 0.05. 
 
Results 
The proximal polymorphisms c.-80_-79insT, c.-136_-132delAGTAG, and c.-168_-
166delAAGinsT essentially determine activity of FABP2 promoter haplotypes in post-
confluent Caco-2 cells. 
As an initial approach to identify the causal polymorphism(s) for the differential activity of 
FABP2 promoter haplotypes we performed promoter-reporter analysis. By means of site-
directed mutagenesis we sequentially introduced alleles of haplotype B into haplotype A and 
vice versa (Fig. 1). We aimed to find minimal necessary change to achieve the activity of the 
other haplotype, respectively. Reporter Firefly luciferase activities of the FABP2 promoter 
haplotypes and from it derived chimeras A-xB and B-xA were determined 120 h after 
transient transfection, when Caco-2 cells were 4 days post-confluent. As shown previously by 
us, both, mRNA as well as protein of FABP2 are clearly up-regulated in differentiated Caco-2 
cells at this time point (Li, et al., 2006). 
As previously reported (Darimont, et al., 1998; Formanack and Baier, 2004; Li, et al., 2006), 
FABP2 haplotype B possessed 28 % activity of haplotype A (Fig. 1). FABP2 promoter 
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chimeras A-80B, A-136B, A-168B, A-260B, A-471B, and A-778B showed activities of 48, 
55, 65, 69, 73, and 78 %. Since highest reduction of haplotype A activity was caused by 
proximal polymorphisms, we generated FABP2 promoter chimeras A-80/136B, A-80/168B, 
and A-136/168B. As shown in Fig. 1, these constructs had the same low activity as haplotype 
B. Next, we performed reporter analysis starting from FABP2 promoter haplotype B with 
consideration of the three polymorphisms c.-80_-79insT, c.-136_-132delAGTAG, and c.-
168_-166delAAGinsT. As shown in Fig. 1, activities of chimeras B-80A, B-136A reached 
59, 42 and 42 % of haplotype A. Chimeras B-80/136A, B-80/168A, and B-136/168A could 
revert the activity of haplotype B into A up to 84 %. However, only a simultaneous 
introduction of alleles -80, -136, and -168 of haplotype A polymorphisms into haplotype B 
(A-80/136/168B) was sufficient to obtain the full activity of A. Thus we reasoned the 
different activities of FABP2 promoter haplotypes are essentially determined by the 
polymorphisms at positions -80, -136 and -168. Because single chimeras A-80B and B-80A 
have the greatest impact onto their activities, the polymorphism c.-80_-79insT is of particular 
importance for transcriptional regulation of FABP2 promoter haplotypes. 
EMSAs confirmed functional importance of FABP2 promoter polymorphisms c.-80_-79insT 
and c.-168_-166delAAGinsT. To see if FABP2 promoter regions containing the alleles of the 
two haplotypes showed differences in transcriptional factor binding capacity, we tested 
nuclear protein extracts from post-confluent Caco-2 cells using EMSA (Fig. 2B). Sequences 
of used oligonucleotides representing the different alleles of FABP2 haplotypes are shown in 
Fig. 2A. EMSA revealed no specific signals with probes containing alleles of polymorphisms 
c.-260G>A. For oligonucleotides comprising polymorphisms c.-471G>A and c.-778G>T 
longer film exposure times were necessary to reveal specific shifts (Fig. 2B, over-exposure). 
A very faint signal was obtained with the -136A but not with the -136B probe. In the case of 
FABP2 promoter oligonucleotides containing alleles of SNP c.-168_-166delAAGinsT two 
specific shifts with high molecular weight were detected for haplotype A and B but no clear 
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differences could be observed in their binding capacities. The strongest signals were obtained 
for -80 probes, whereby one main complex was formed (Fig. 2B). Interestingly, the 
oligonucleotide containing the -80 allele of haplotype B bound less nuclear proteins than A. 
Taken together, EMSA revealed strong binding of transcription factors to proximal FABP2 
promoter polymorphisms c.-80_-79insT and c.-168_-166delAAGinsT. Clear differences in 
binding capacity between the regions encompassing the polymorphisms were obtained for the 
-80 probes with strongest protein interaction with the -80A probe. Thus, EMSAs support the 
results from the reporter gene analysis with chimeric promoter constructs and reinforce the 
functional importance of polymorphism c.-80_-79insT in determining different activities of 
FABP2 haplotype A and B. 
Transcription factors bind with higher affinity to the FABP2 promoter region containing the -
80 allele of haplotype A in comparison to B. To further analyze the binding characteristics of 
the FABP2 promoter region containing the c.-80_-79insT polymorphism we performed 
EMSA with nuclear protein extract from Caco-2 cells designed as competition and cross-
competition experiments. As shown in Fig. 3A, we observed a complete displacement of 
transcription factor binding to probes -80A (lane 1-5) and -80B (lane 6-9) with 50 (lane 2, 8) 
or 100 (lane 4, 5, 9) molar excess of unlabelled probes. However, longer film exposure times 
(Fig. 3A, lower panel) showed that binding to the -80A probe is more eliminated by a 100 
molar excess of competitor -80A (lane 4) in comparison to -80B (lane 5). To compare 
affinities more clearly, lower concentrations of competitors were used. As shown in Fig. 3B, 
specific shifts obtained by the -80A probe were competed away by gradually increasing 
excess of unlabelled probes. Already a 20-fold excess of unlabelled –80A probe completely 
abolished the shift, whereas a 50-fold excess of competitor B was necessary. Therefore, we 
conclude that nuclear proteins seem to bind with higher affinity to the FABP2 promoter 
region containing the -80A allele of haplotype in comparison to B.  
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GATA factors show stronger interaction with FABP2 promoter region containing the allele -
80A in comparison to -80B. To reveal putative transcription factor binding site(s) in the -80 
region of the FABP2 promoter we performed an in-silico analysis using Transfac database 
(Kel, et al., 2003; Matys, et al., 2006). A GATA consensus site (A/T)GATA(A/G) 
(Molkentin, 2000) was found that bears within its matrix the c.-80_-79insT polymorphism. 
Whereas the five most conserved bases of GATA consensus matches with both variants 
completely, the score for matrix match is slightly higher for haplotype A (0.995) than B 
(0.981) suggesting differential binding of GATA factors. 
Based on these results we investigated binding of GATA-5 and 6 to FABP2 -80A and -80B 
probes. EMSA were carried out with nuclear protein extracts from Hela cells transfected with 
GATA-5 and 6 because these factors are not expressed in this particular cell line. As shown 
in Fig. 4, no shifts were detected in non-transfected cells (lane 3, 4). Specific shifts for probes 
-80A (lane 5, 6, 9, 10) and -80B (lane 7, 8, 11, 12) were obtained with extracts from GATA-5 
and GATA-6 transfected cells. The Gata-6 DNA complexes showed exactly the same size as 
shifts obtained with extracts from Caco-2 cells (lane 1, 2) whereas the complex formed with 
GATA-5 extract was detected slightly below. This difference corresponds with the predicted 
molar mass of 42 and 45 kDa for GATA-5 and -6, respectively. Even more interesting, 
FABP2 oligonucleotide containing the -80A allele shows higher binding capacity for both 
factors, GATA-5 and GATA-6 in comparison to the -80B allele (compare lanes 5 and 7, 9 
and 11, respectively). Thus, these data confirm the competition experiments with nuclear 
extracts from post-confluent Caco-2 cells. 
The GATA-induced two times lower activation of FABP2 promoter haplotype A in 
comparison to B is determined by polymorphisms c.-80_-79insT. To prove, if different 
binding capacities of GATA factors to FABP2 promoter region containing the c.-80_-79insT 
polymorphism reflect different activation potential of FABP2 haplotype A and B we 
performed reporter gene analysis. To circumvent the problem of high and different activities 
Regulation of FABP2 haplotypes via GATA factors                                                        12  
  
of FABP2 promoter haplotypes as detected in Caco-2 cells, GATA-5 and -6  induced 
activities of haplotypes were analyzed in hepatic Huh7 cells. As shown in Fig. 5, this cell line 
shows very low and similar activity of FABP2 promoter haplotypes. GATA-5 as well as 
GATA-6 increased clearly basal activities of both FABP2 promoter haplotypes, whereby 
GATA-5 overall induced higher transcriptional activity than GATA-6. Interestingly, FABP2 
promoter haplotype A is two times more activated by GATA factors than haplotype B. This 
difference reflects nearly those obtained in Caco-2 cells. To analyse the specific importance 
for polymorphism c.-80_-79insT for different GATA5-induced activation of FABP2 
haplotype A and B we analyzed relevant chimeras A–80B, B–80A, and B-80/136/168A. As 
shown in Fig. 5, chimeras B-80A and B-80/136/168A show similar activation by GATA-5 
than haplotype B. Consistent with different binding affinities of GATA factor to the –80 
region, a construct bearing the –80B allele in the background of haplotype A reversed the 
activity from A to B.  
 
Discussion 
Here we provide a comprehensive functional investigation regarding promoter haplotype 
depending regulation of human FABP2. These haplotypes are associated with type 2 diabetes, 
postprandial triglyceride levels, and BMI (Damcott, et al., 2003; Geschonke, et al., 2002; Li, 
et al., 2006). As shown previously by us (Li, et al., 2006) and others (Damcott, et al., 2003; 
Formanack and Baier, 2004), the basal transcription of the rare FABP2 promoter haplotype B 
is about 2-3 fold lower than the common haplotype A. Consequently, we investigated which 
polymorphism(s) and transcription factor(s) are causal for this different regulation. 
 
By means of reporter assays using chimeric FABP2 promoter constructs we found that 
difference in haplotype activities is essentially determined by the first three proximal FABP2 
promoter polymorphisms, whereby c.-80_-79insT has the greatest impact. Accordingly, clear 
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differences in allele specific binding of nuclear proteins from post-confluent Caco-2 cells 
were observed for c.-80_-79insT, whereas regions containing other FABP2 promoter 
polymorphisms showed no substantial (c.-778G>T, c.-471G>A, –260G>A) or allele specific 
(c.-168_-166delAAGinsT) binding. Further, we demonstrated higher binding capacity of 
GATA-5 and GATA-6 to the FABP2 promoter region containing the -80A allele in 
comparison to the -80B allele. These GATA factors induce the activity of FABP2 promoter 
haplotype A two times more than haplotype B. Therefore, different transcriptional activities 
of FABP2 promoter haplotypes are mainly caused by the c.-80_-79insT polymorphism 
mediated by GATAs. GATA-4, -5 and –6 are zinc finger-containing transcription factors and 
are present in various meso- and endoderm derived tissues such as intestine, heart, liver, lung 
and gonad. GATA-4, -5 and -6  are important transcriptional regulators of differentiation and 
embryonic development and tissue-specific gene expression (Bossard and Zaret, 1998; Bosse, 
et al., 2006; Gao, et al., 1998; Molkentin, 2000). These factors are also present in Caco-2 
cells with GATA-6 as the predominant form (Fang, et al., 2001; Fitzgerald, et al., 1998; Gao, 
et al., 1998; Kamitani, et al., 2000). A specific expression pattern of GATA-4, -5 and -6 were 
described in intestinal cells. GATA-6 is present at high levels in proliferating and less 
differentiated cells, whereas GATA-4 and -5 are strongly up-regulated along the crypt-villus-
axis during cell differentiation (Gao, et al., 1998). FABP2 expression is also highest 
expressed in villus region (Shields, et al., 1986; Sweetser, et al., 1988), reinforcing GATA 
induced activation of the FABP2 promoter. Furthermore, GATA factors bind to highly 
conserved elements in FABP2 promoters of mouse (mFABP2) and zebrafish (zFABP2) at 
regions corresponding to the human FABP2 promoter segment encompassing the c.-80_-
79insT polymorphism (Belaguli, et al., 2007; Her, et al., 2004). Mutations of this site 
abolished the mFABP2 promoter reporter activity after transient transfection completely 
(Belaguli, et al., 2007). Intriguingly, mutation in the highly conserved GATA site of the 
zFABP2 promoter resulted in a non-specific expression of a zFABP2 reporter in other tissues 
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(Her, et al., 2004). These studies emphasize the crucial role of GATA in regulation of FABP2 
in vertebrates. Interestingly, GATA-4 cooperates with Smad transcription factors, the 
downstream effectors of the TGFβ signalling pathway, to activate the mFABP2 promoter 
(Belaguli, et al., 2007). TGFβ is a critical regulator of development and maintenance of 
intestinal epithelium (Hauck, et al., 2005). Notably, polymorphic sites in the TGFβ gene are 
associated with diabetes and obesity phenotypes, e.g. body composition, increased insulin 
and glucose levels (Long, et al., 2003; Rosmond, et al., 2003). Therefore on the basis of 
possible functional interaction between TGFβ, GATA factors and FABP2 it seems to be a 
promising approach to study effects of polymorphism combinations in these genes on traits of 
the metabolic syndrome. 
 
Although our experiments strongly indicate a predominant role of c.-80_-79insT 
polymorphism in determining different activities of FABP2 promoter haplotypes, we have not 
ignored that polymorphisms c.-136_-132delAGTAG and c.-168_-166delAAGinsT are also of 
functional relevance. This assumption is based on two observations. Firstly, reporter assays 
using chimeras of FABP2 promoter haplotypes revealed, that double or triple substitutions at 
positions -80, -136, and -168 are necessary for complete reconstitution of haplotype activity. 
This is particular true for chimeras which bear haplotype B alleles in the background of 
haplotype A. Secondly, although chimera A-80B reversed the GATA induced activation from 
haplotpye A into that of B, the reverse chimera could not re-establish the activation potential 
of A. Also, the GATA-5 induced activity of chimera B-80/136/168A is similar to FABP2 
promoter haplotype B and not to A. We cannot fully explain this data. However, taking into 
account that transcriptional regulation is not the result of binding of single transcription 
factors to isolated motifs, GATA factors may differentially regulate FABP2 promoter 
haplotypes in synergistic action with other factors. Interactions of GATA with abundantly 
expressed CDX-2 and HNF-1 have been already described and are responsible for tissue-
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specific high expression of intestinal genes (Boudreau, et al., 2002; Divine, et al., 2004; 
Krasinski, et al., 2001; van Wering, et al., 2004; van Wering, et al., 2002). In-silico analysis 
as well as experimental verifications (Klapper et al, unpublished) revealed functional but not 
allele specific HNF-1 binding sites in the FABP2 promoter region bearing the polymorphism 
c.-168_-166delAAGinsT. We propose a synergistic activation of FABP2 promoters by 
GATA factors, HNF1, and CDX-2 resulting in high expression of FABP2, whereby 
difference in transcriptional activity of FABP2 haplotypes may be essential determined by 
GATA factors. It should be noted, that there is no evidence for genotype specific expression 
of FABP2 in-vivo, since it is very difficult to obtain healthy tissue samples from the intestine. 
However, since GATA factors play an essential role in differentiation processes of intestine 
and supposed to be important for intestine-specific high expression (Bossard and Zaret, 1998; 
Bosse, et al., 2006; Gao, et al., 1998; Molkentin, 2000), we propose that in vivo expression is 
similar robustly regulated with respect onto the differential regulation of FABP2 promoter 
haplotypes A and B.  
 
Thus, the GATA mediated differential activation of FABP2 haplotypes depends on 
polymorphism c.-80_-79insT. This provides the molecular basis for the variant specific 
transcriptional regulation of the diabetes type 2 associated FABP2 gene.
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Figure legends 
 
Figure 1. Reporter activities of FABP2 promoter haplotypes and from it derived chimeras in 
post-confluent CaCo-2 cells. Alleles of each polymorphism in the FABP2 promoter 
haplotypes A>B are given. The positions of polymorphisms c.-80_-79insT (rs5861422), c.-
136_-132delAGTAG (rs5861423), c.-168_-166delAAGinsT (rs1973598), c.-260G>A 
(rs6857641), c.-471G>A (rs2282688), c.-778G>T (rs10034579) are named as -80, -136, -168, 
-260, -471, -778, respectively (positions relative to translation start codon). Luciferase 
activities of FABP2 promoter haplotypes (A, B) and from it derived chimeras (A-xB, B-xA) 
were assessed 120 h after transfection using dual luciferase assay. The Firefly luciferase 
activities were normalized to Renilla luciferase activities and are given as relative luciferase 
activities in % of FABP2 promoter haplotype A. Each experiment was performed in triplicate 
for each sample. The results are expressed as mean ± SEM for at least three independent 
experiments. ***, p<0.001, **, p<0.01, *, p < 0.05, as compared with haplotype A activity. 
+++, p<0.001, ++, p<0.01, +, p < 0.05, as compared with haplotype B activity. 
 
Figure 2. Differential interactions of transcription factors with FABP2 promoter regions 
containing the alleles A and B of polymorphisms c.-80_-79insT (rs5861422), c.-136_-
132delAGTAG (rs5861423), c.-168_-166delAAGinsT (rs1973598), c.-260G>A (rs6857641), 
c.-471G>A (rs2282688), c.-778G>T (rs10034579) were analyzed with EMSAs. The 
oligonucleotides used in EMSAs were shortly named with -80A/B, -136 A/B, -168 A/B, -260 
A/B, -471 A/B and -778A/B. A, The sequences for oligonucleotides are given. B, Interaction 
of nuclear proteins from post-confluent Caco-2 cells with FABP2 probes bearing the 6 
promoter polymorphisms. 2 µl nuclear extract isolated from post-confluent Caco-2 cells were 
used for each binding reaction with 20 fmol of biotinylated oligonucleotides. Specific shifts 
were diminished by 100-fold excess of unlabelled oligo and are indicated with an arrowhead. 
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EMSAs with nearly equal film exposure times (1-2 min) are shown. The lower images 
represent results of EMSAs for -471A/B and -778A/B probes after longer exposure times (40 
min) to reveal weak protein-DNA complexes. 
 
Figure 3. Transcription factors bind with higher affinity to –80A (A) than to –80B (B) oligo 
(see Fig. 1A). 2 µl nuclear extract isolated from postconfluent Caco2 cells were used for each 
binding reaction (no extracts were added in lanes 1 and 6) with 20 fmol of biotinylated oligos 
in EMSA. Competition and cross-competition experiments were carried out. A Biotinylated 
A probe was competed away with 50-fold (lane 3) and 100-fold excess of unlabelled A (lane 
4) and B oligo (lane 5). Biotinylated B probe was competed away with 50-fold (lane 8) and 
100-fold excess of unlabelled B (lane 9). The lower image represents film overexposure 
marked italic numbered lanes. B Biotinylated A probe were competed away with increasing 
amounts of A or B oligo as indicated.  
 
Figure 4. GATA factors show stronger interaction with -80A (A) than with -80B (B) oligo 
(see Fig.1A). 2 µl nuclear extracts isolated from post-confluent Caco2 cells (lanes 1 and 2), 
Hela cells (lanes 3 and 4) and Hela cells transfected with GATA-5 (lanes 5-8) and GATA-6 
(lanes 9-14) were used for binding reactions with 20 fmol of biotinylated oligos A or B 
probe. Specific shifts were diminished by 100-fold excess of unlabelled A or B oligo and are 
indicated with an arrowhead. 
 
Figure 5. FABP2 promoter variant A is more activated by GATA factors than variant B in 
Huh7 cells. Luciferase activities of FABP2 promoter haplotypes A and B and chimeric 
constructs of both variants were assessed 48 h after transfection in Huh7 cells using dual 
luciferase assay. The Firefly luciferase activities were normalized to Renilla luciferase 
activities and are given as relative luciferase activities in % of GATA-5 activated variant A. 
Regulation of FABP2 haplotypes via GATA factors                                                        21  
  
Each experiment was performed in triplicate for each sample. The results are expressed as 
mean ± SEM for at least three independent experiments. ***, p<0.001, **, p<0.01, *, p < 
0.05, as compared with haplotype A activity. +, p < 0.05, as compared with haplotype B 
activity. 
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Abstract
The cytosolic human intestinal fatty acid binding protein (hFABP2) is proposed to be involved in intestinal absorption of long-chain
fatty acids. The aim of this study was to investigate the regulation of hFABP2 by the endodermal hepatocyte nuclear factor 4a (HNF-
4a), involved in regulation of genes of fatty acid metabolism and diﬀerentiation. Electromobility shift assays demonstrated that HNF-4a
binds at position 324 to 336 within the hFABP2 promoter. Mutation of this HNF-4 binding site abolished the luciferase reporter
activity of hFABP2 in postconﬂuent Caco-2 cells. In HeLa cells, this mutation reduced the activation of the hFABP2 promoter by
HNF-4a by about 50%. Thus, binding element at position 336/324 essentially determines the transcriptional activity of promoter
and may be important in control of hFABP2 expression by dietary lipids and diﬀerentiation. Studying genotype interactions of hFABP2
and HNF-4a, that are both candidate genes for diabetes type 2, may be a powerful approach.
 2007 Elsevier Inc. All rights reserved.
Keywords: hFABP2; HNF-4a; Fatty acid metabolism; EMSA; Reporter assay
The human intestinal fatty acid binding protein
(hFABP2) gene is localized on chromosome 4q28-q31
and contains four exons [1]. The FABP2 gene encodes a
15 kDa cytosolic protein, which is exclusively expressed
in enterocytes with highest cellular concentrations in jeju-
num with falling levels to the proximal duodenum and
colon [2,3]. FABP2 is up-regulated during development
[4] and crypt-to-villus transition. Whereas FABP2 is absent
in crypt cells, highest protein abundance is found in upper
villus region [2,5,6], where fat absorption takes place. The
function of FABP2 is still not fully elucidated. It is pro-
posed to be involved in intestinal fat absorption by cellular
binding and traﬃcking of newly absorbed non-esteriﬁed
long-chain fatty acids, which are ﬁnally assembled and
secreted in triglyceride-rich chylomicrons [7–9].
The homodimeric transcription factor HNF-4a is an
abundant nuclear protein in the endoderm derived tissues
liver, intestine, pancreas and kidney and controls an unu-
sual high proportion of hepatic and pancreatic expressed
genes as shown by ChIP [10]. In enterocytes, HNF-4a
seems to be a critical regulator of diﬀerentiation processes
[11–13]. Cellular diﬀerentiation in small intestine leads to a
fully functional cell type in villus region that can entirely
meets the requirements in absorption of macro- and micro-
nutrients. Accordingly, this diﬀerentiated cell type is char-
acterized by a speciﬁc expression pattern of several genes,
including genes involved in lipid metabolism. Genes that
are up-regulated during development and crypt-to-villus
diﬀerentiation and that are furthermore annotated with
the gene ontology (GO) term ‘‘lipid metabolism’’ have an
overrepresentation of potential HNF-4 binding sites in
their promoters and are correlated with highest levels of
lipids in villus tips of intestine [11]. HNF-4a, originally
considered as orphan nuclear receptor, was previously
shown to bind fatty acid acyl-CoA esters as ligands. These
were able to modulate HNF-4a DNA binding activity in
dependence on their chain length and saturation grade
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[14]. HNF-4a is involved in regulation of genes that partic-
ipate in chylomicron synthesis in enterocytes such as MTP
[15], Apo B [16], Apo C III [16] Apo A I [17], or Apo A IV
[18]. For the Apo A IV gene, it was shown that HNF-4
mediates its transcriptional regulation by dietary lipids
[19]. Thus, the cellular fatty acid concentration seems to
be linked through HNF-4a with transcriptional control
of genes involved in fat metabolism.
In the present study, we wanted to address the question
if and how human FABP2 is regulated by HNF-4a. We
show the presence of a HNF-4 binding site by electromo-
bility shift assays. Reporter analysis indicates that this ele-
ment essentially determines the transcriptional activity of a
836 bp hFABP2 promoter luciferase construct in postcon-
ﬂuent Caco-2 cells. Mutations of this HNF-4-binding site
nearly abolished the promoter activity of hFABP2 suggest-
ing a major role for HNF-4a in the control of hFABP2
expression in the small intestine.
Materials and methods
Cell culture. HeLa cells and Caco-2 were purchased by German
National Resource Centre for Biological Material (DSMZ, Braunschweig,
Germany) and American Type Culture Collection (ATCC, Rockville,
MD), respectively. Cells were maintained in MEM (Invitrogen, Carlsbad,
CA), supplemented with 10% (HeLa) and 20% fetal calf serum (Caco-2)
(Invitrogen) and 1 mM non-essential amino acids (PAA, Co¨lbe, Germany)
in a humidiﬁed incubator at 37 C under an atmosphere of 5% CO2. Cells
were passaged at preconﬂuent densities by use of 0.05% trypsin/0.02%
EDTA solution (Biochrom AG, Berlin, Germany) every 2–3 days.
hFABP2 promoter luciferase constructs. The dual luciferase system was
used (Promega, Madison, WI). Cloning procedures were performed using
Gateway Technology (Invitrogen), described previously [20]. attR-sites
were inserted into a EcoRV blund-end site of the reporter plasmid
(pGL4.10[luc2]) encoding Firefly luciferase. A 836 bp fragment upstream
from initiation codon of the hFABP2 promoter (haplotype A) was sub-
cloned by recombination with LR Clonase into attR-sites of
pGL4.10[luc2] from vector pENTR-hFABP2-Prom-attL contained attL-
sites resulting in ﬁnal pGL4.10[luc2]-hFABP2 promoter reporter con-
struct. The empty pGL4.10[luc2] vector served as a negative control.
Introduction of mutation into HNF-4 consensus site of pGL4.10[luc2]-
hFABP2 resulting in pGL4.10[luc2]-hFABP2-MutHNF-4 was performed
using Quick Change in vitro mutagenesis Kit (Stratagene, La Jolla, CA).
All primers were purchased from MWG Biotech AG (Ebersberg, Ger-
many). Sequences of primers are available on request. Veriﬁcation of
constructs was performed by sequencing.
Expression plasmids. Expression vectors pRc/CMV-HNF-1a and pRc/
CMV-HNF-4a2 were a kind gift from Dr. G. Ryﬀel (University of Essen,
Germany). Open reading frames of HNF-1a and HNF-4a2 were ampliﬁed
by PCR and subcloned in expression vector pDest40 using Gateway
technology. Preparation of human PPARc2 expression vector is described
by Nitz et al. [21]. Human expression plasmid RXRa was kindly provided
by Dr. J. Weitzel (University Medical Center Hamburg-Eppendorf,
Germany).
Transient transfections and reporter assays. Transient transfections
were performed with FuGene6 (Roche, Basel, Switzerland) according to
the manufacturer’s instructions. 1 · 104 Caco cells were plated in 96-well
plates. Cells were co-transfected with 47.5 ng pGL4.10[luc2]-hFABP2,
pGL4.10[luc2]-hFABP2-MutHNF-4 or pGL4.10[luc2] as negative control
and 2.5 ng pGL4.74[hRluc/TK] vector encoding Renilla luciferase as
internal control. Luciferase activities were measured 120 h after transfec-
tion by Dual-Luciferase Reporter Assay System (Promega). 4 · 103 HeLa
cells/96 well were used for co-transfections with HNF-4a2, HNF-1a, and
PPARc/RXRa. Cells were co-transfected with 30 ng pGL4.10[luc2]-
hFABP2-promoter construct, pGL4.10[luc2]-hFABP2-Prom-MutHNF-4,
or pGL4.10[luc2], 66 ng of the expression vectors pDest40-HNF-4a2 and
pDest40-HNF-1a, with 33 ng of PPARc2 and RXRa each or 66 ng empty
pDest40 vector and 3 ng pGL4.74[hRluc/TK] vector. Each experiment
was repeated at least twice, and each sample was studied in triplicate.
Electromobility shift assay (EMSA). The biotinylated probe was pre-
pared by end labeling oligonucleotides with biotin by the Biotin 3 0 End
DNA Labeling Kit (Pierce, Rockford, IL). Annealing of the unlabeled and
labeled oligomers was done following the technical resource ‘‘Annealing
complementary pairs of oligonucleotides’’ (Pierce). The following oligo-
nucleotides were used as DNA probes: 700/687: 5 0-CAT
GGCAGATGTTTAAAGCTCATTCTTTCTTT-3 0, 468/480: 5 0-
GAATCTTATTAACTTTAGCTTTTCAAC-30, 336/324: 5 0- CAAC
ATAGTCTGCACTTTGAACTTAGAAAAAC-30, mutated 336/324:
5 0-CAACATAGTCTGCAAGGGTAACTTAGAAAAAC-3 0, 120/
102: 5 0-GTGATTTCCTGAACTTTAAGCTTCCACATCAC-30 and
unrelated oligo: 5 0-CAGAACGAGAATTAAGAATTAATAAGAATA
AGAATTAATTAATTGCTTG-3 0. Nuclear extracts were prepared
from postconﬂuent Caco2 cells with the NE-PER Nuclear and Cyto-
plasmic Extraction Reagents Kit (Pierce). The EMSAs were performed
with the LightShift Chemiluminescent EMSA Kit (Pierce) according to
manufactures instructions. The reaction mixture (20 ll) contained 1 mM
Tris, 50 mM KCl, 1 mM DTT, 1 lg Poly(dI–dC), 2.5% Glycerol, and
0.1 mM EDTA. The DNA-transcription factor complexes were resolved
on a native 4% Tris-borate-EDTA polyacrylamide gel in 0.5· TBE buﬀer
and transferred to a nylon membrane (Amersham Bioscience, Piscataway,
NJ). Biotinylated DNA was detected with streptavidin-horseradish
peroxidase conjugate and chemiluminescent substrate Luminol using
Chemiluminescence Nucleic Acid Detection Module. In supershift
reactions the following antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA) were used: HNF-4a(C-19): sc-6556 and HNF-1a(C-19):
sc-6547.
Statistical analyses. Statistical analyses were performed in GraphPad
Prism 4 (Graphpad Software, Inc., San Diego, CA) using ANOVA and
t-test. All values were expressed as means ± SD. Signiﬁcant diﬀerences
were considered for p values less than 0.05.
Results and discussion
In silico analysis of the hFABP2 gene promoter region
As a ﬁrst approach to identify HNF-4 binding sites
within the human FABP2 gene promoter region, a data-
base search was performed with an 836 bp segment
upstream of the translation start by using the TRANSFAC
Professional database [22,23]. As cut-oﬀs minimisation of
sum of false positives and negatives and scores of core
and matrix match for HNF-4 recognition sites of at least
0.9 were chosen. Three putative HNF-4 binding sites were
found at positions 700/687, 336/324, and 120/
102 of the hFABP2 promoter. In addition, we proved
an element, which was already postulated as conserved
HNF-4 binding sites in rodent and human FABP2 promot-
ers, at position 480/468 [24]. Taken together, as shown
in Fig. 1, four putative HNF-4 binding sites were found in
the hFABP2 promoter.
EMSA confirms binding of HNF-4 to position 324/–336 of
the hFABP2 gene promoter
To prove binding of HNF-4 to the four putative sites
within the hFABP2 gene promoter, we performed EMSAs
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with nuclear protein extracts from post-conﬂuent and dif-
ferentiated Caco-2 cells. In this cell line HNF-4a is up-reg-
ulated by diﬀerentiation [25]. We observed no binding for
hFABP2 promoter elements at positions 700/687,
468/480, and 120/102 (data not shown). In contrast
to Rottman and Gordon [24] who detected a HNF-4 bind-
ing site in a conserved rat FABP2 element position (82/
69) we could not detect binding of HNF-4a to this pro-
moter element at corresponding position 120/102 in
human FABP2. However, promoter sequence is not fully
conserved and binding aﬃnity of HNF-4a may be drasti-
cally lower.
As shown in Fig. 2A, we could detect a strong and spe-
ciﬁc shift in case of HNF-4 site at position 336/324 of
the hFABP2 gene promoter. Lane 2 shows a speciﬁc shift
that could be competed by 100 molar excess of unlabeled
probe (lane 3). An excess of unlabeled probe containing a
5-bp mutation (lane 4) and of unrelated oligonucleotide
(lane 5) could not interfere with binding of proteins. Addi-
tion of HNF-4a antibody abolished the strong speciﬁc shift
completely. A supershift of the signal was not detected
(Fig. 2B, lane 2). This may be either due to impairment
of HNF-4-binding to consensus site by HNF-4a antibody
or supershift signal may be located in unspeciﬁc signals.
To assure that the eﬀect was caused speciﬁcally by HNF-
4a antibody, HNF-1 was added to binding reaction (lane
3). In this case formation of the speciﬁc complex was not
disturbed. Therefore, we conclude that HNF-4a binds
Fig. 1. Putative HNF-4 binding sites in the human intestinal fatty acid binding protein 2 (hFABP2) gene promoter. The nucleotide sequence –836 to –1
relative to translation start site is shown. The sequence was analysed with TRANSFAC database and compared with the HNF-4 factor matrix. An
element, which was already postulated as conserved HNF-4 binding sites in rodent and human FABP2 promoters [24], at position 480/468 was also
proved. The sequence on (+)-strand of the suggested consensus site is given. Capitals indicate the core sequence, the most conserved region. As cut-oﬀs
were chosen: to minimize the sum of false positives and negatives. The scores of core and matrix match for HNF-4 were at least 0.9. Arrows indicate the
transcriptional start site.
Fig. 2. Speciﬁc interaction of HNF-4a to the human hFABP2 gene promoter at position 336/324. Two microliters of nuclear extracts isolated from
postconﬂuent Caco2 cells were used for each binding reaction with 20 fmol of biotinylated oligos (no extract was added in B, lane 1) in electromobility shift
assays. (A) Competition experiments were carried out without unlabeled oligo (lane 2), with 100-fold excess of unlabeled oligo (lane 3), mutated oligo (lane
4) and unrelated oligo (lane 5). Speciﬁc shift is indicated with an arrowhead. (B) Supershift was performed with 2 lg of HNF-4a antibody (lane 2). HNF-1
antibody was used as control (lane 3).
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speciﬁcally to oligonucleotide corresponding to positions
336/324. This element has no corresponding element
in rat or mouse promoter sequence at similar position [1].
The HNF-4 binding site in position 324 to –336 is essential
for transcriptional activity of hFABP2 promoter in Caco-2
cells
To investigate the functional importance of HNF-4
binding site at promoter position 336/324 for hFABP2
expression, we performed promoter-reporter assays with
dual luciferase system. The Firefly luciferase constructs
contained an functional 836 bp segment of the hFABP2-
promoter [20]. A 5-bp mutation was introduced into the
core sequence, CTTTGﬁ AGGGT, of HNF-4 consensus
at position 336/324 within reporter construct
pGL4.10[luc2]-hFABP2 resulting in pGL4.10[luc2]-
hFABP2-MutHNF-4. Luciferase activities were measured
6 days after seeding, when Caco-2 cells were 4 days post-
conﬂuent. As shown by us previously, both, FABP2
mRNA as well as protein level are clearly up-regulated in
Caco-2 cells at this time point [20], very likely due to spon-
taneous diﬀerentiation in this cell line after having reached
conﬂuence [26]. Also HNF-4a expression is notably
increased at this stage [25]. As shown in Fig. 3A, the activ-
ity obtained from the FABP2 promoter construct was
44-fold higher in comparison to the control construct. The
mutation in HNF-4 binding site at position 336/324
nearly abolished the Firefly luciferase activity in Caco-2
cells. This result is consistent with the report that FABP2
is absent in visceral endoderm of embryonic bodies of dif-
ferentiated ES-cells of HNF-4a / mice [27]. Together
these ﬁndings give rise to assumption that HNF-4a is
essential for FABP2 expression. This dramatic eﬀect may
be explained by synergistic action of HNF-4a with other
transcription factors. HNF-4a was previously described
to synergistically interact with Sp1 [28], HNF-1 [29,30],
or HNF-3 [31] to induce reporter activity of apoCIII,
FABP1 and apoAI promoters, respectively, and HNF-4
binding sites were proved to be essential for functional syn-
ergism with these factors.
Mutation in positions 336/324 reduced the activation of
the hFABP2 promoter by HNF-4a in HeLa cells
In order to study the inﬂuence of position 336/324
on HNF-4a induced hFABP2 promoter activity directly
we used HeLa cells that do not express FABP2 [24] and
HNF-4a. As shown in Fig. 3B, hFABP2 promoter exhibits
a 7.3-fold increase in luciferase activity when co-transfected
with HNF-4a plasmid. A mutation in the HNF-4 binding
site at positions 336/324 reduced the activation of the
hFABP2 promoter by HNF-4a of about 50%. If activation
of mutant is attributable to more HNF-4 binding sites in
the analysed promoter region or if activation of other tran-
scription factors by HNF-4a overexpression leads to induc-
tion of reporter activity, we cannot specify. The speciﬁcity
of the diﬀerential regulation of hFABP2 promoter con-
structs by HNF-4 was shown by activation experiments
with HNF-1. We observed no diﬀerence in HNF-1 induced
activities of hFABP2 wild type and mutant promoter. The
HNF-4 consensus element encompasses an direct repeat of
6 bases spaced by one nucleotide (DR-1) on (-) strand
(agttca(a)agttca). Because DR-1 repeats can be recognized
not only by HNF-4a but also by PPAR/RXR heterodimers
[32,33] we tested the activation of FABP2 promoter
Fig. 3. Reporter assay of hFABP2 promoter wild type (WT) and HNF-4 mutant (Mut) constructs after transient transfection using dual luciferase assay.
(A) Basal activities of FABP2 promoter constructs were assessed in postconﬂuent Caco-2 cells 120 h after transfection. ***p < 0.001, as compared with wild
type FABP2 promoter activity. (B) Induction of promoter activity of hFABP2 promoter constructs by HNF-4 was assessed in HeLa cells. Luciferase
activities were measured 48 h after transfections. *p < 0.05, as compared with wild type FABP2 HNF-4a induced promoter activity. The Firefly luciferase
activities were normalized to Renilla luciferase activities and are given as relative luciferase activities. Each experiment was performed in triplicate for each
sample. The results are expressed as means ± SD for two (A) or three (B) independent experiments.
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constructs by PPARc/RXRa. No diﬀerences in activation
of wild type and mutant with or without 2 lM of PPARc
ligand Rosiglitazone were found (Fig. 3), indicating that
PPAR/RXR heterodimers do not bind to this DR-1 repeat.
This result is consistent with EMSA that revealed only one
DNA–protein complex.
Previous investigations in transcriptional regulation of
human FABP2 concerned basal activities of two FABP2
promoter haplotypes [20,34–36]. This genetic variation in
the hFABP2 gene is associated with postprandial triglycer-
ide levels [36], body composition, lipid plasma levels [34],
and diabetes [20]. However, little eﬀort was done to reveal
the substantial promoter regulation of hFABP2. FABP2
expression was shown to be induced by oleic acid in
Caco-2 cells; however, no mechanism mediating this regu-
lation has been proposed [37]. As already mentioned,
HNF-4a is involved in transcriptional regulation of Apo
A IV by lipid micelles, when micelles supplied to apical
pole of Caco-2 cells. If HNF-4a also plays a role in regula-
tion of hFABP2 by dietary lipids needs to be proved.
Interestingly, HNF-4a and hFABP2 are candidate genes
for diabetes type 2 (non-insulin dependent diabetes melli-
tus, NIDDM). The hFABP2 T54 allele of exon 2 A54T
polymorphism could be linked to insulin resistance in dif-
ferent populations [38–40]. Also hFABP2 promoter haplo-
types were associated with NIDDM [20]. In HNF-4a, 3
SNPs near the P1 promoter and exons 1–3 could be associ-
ated with diabetes type 2 in a ﬁnish population [41]. On the
basis of the here demonstrated functional interaction of
hFABP2 and HNF-4a it seems to be a powerful approach
for genetic epidemiologists to study eﬀects of genotype
combinations of both genes on the development of
NIDDM.
In conclusion, in the present study we have systemati-
cally investigated the presence of HNF-4a binding sites in
the human FABP2 promoter and identiﬁed a functional
HNF-4a element at the position 336/324. The modula-
tion of FABP2 expression by diﬀerent types of fatty acids
and especially the physiological importance of the HNF-
4a binding site in regulation of FABP2 by dietary lipids
should be in focus of future investigations.
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Abstract 
The human fatty acid binding protein (FABP2) is involved in intestinal absorption and 
intracellular trafficking of long-chain fatty acids. FABP2 knock-out mice and 
association analysis of functional promoter haplotypes revealed that FABP2 is a 
susceptibility gene for insulin resistance and related traits. Here we investigate 
transcriptional regulation of FABP2 by the endodermal hepatic nuclear factor 1 alpha 
(HNF-1α). In electromobility shift and supershift assays we show the presence of two 
overlapping HNF-1α binding sites within the FABP2 promoter regions -185 to -165 
and -169 to -149. Reporter gene analysis in Caco-2 and Hela cells demonstrated that 
HNF-1α activates an 836 bp FABP2 promoter construct by 3.5 and 20-fold, 
respectively. This induction is identical between FABP2 promoter haplotypes. 
Mutational analysis of HNF-1α element -185 to -165 resulted in about 50 % reduction 
of basal activity of the FABP2 promoter construct in Caco-2 cells, whereas disruption 
of the -169 to -149 element had marginal effect. Co-transfection experiments in Hela 
cells with HNF-1α revealed similar effects on activity of FABP2 promoter mutants. In 
conclusion, our data suggest a major role of HNF-1α in control of FABP2 expression 
in intestine via a functional HNF-1α recognition element within FABP2 promoter 
region -185 to -165.  
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Introduction 
The human intestinal fatty acid binding protein FABP2 belongs to a family of small 15 
kDa cytosolic proteins that have multiple functions in metabolism and regulation. 
They bind and transport free fatty acids to metabolic enzymes and specific 
subcellular compartments including the nucleus [reviewed in (Haunerland and 
Spener, 2004)]. Furthermore they seem to be involved in regulation of growth and 
differentiation (Haunerland and Spener, 2004). Although the specific function of 
FABP2 is still not fully elucidated, it is proposed to be involved in fat absorption by 
binding and intracellular transport of newly absorbed non-esterified long-chain free 
fatty acids (Baier et al., 1996; Levy et al., 2001; Lowe et al., 1987). Hereby, fatty acid 
transfer from membranes to FABP2 and vice versa occurs by protein-membrane 
collisional interaction (Thumser and Storch, 2000). The gene encoding human 
FABP2 contains four exons and is localized on chromosome 4q28-q31 (Sweetser et 
al., 1987). FABP2 is specifically expressed in the intestine and is up-regulated during 
development and cell differentiation (Cohn et al., 1992; Gordon et al., 1985; 
Sweetser et al., 1988). The highest levels of the FABP2 protein were found in 
absorptive cells of the upper villus region (Haegebarth et al., 2006; Shields et al., 
1986; Sweetser et al., 1988). 
 
FABP2 is a candidate gene for diabetes type 2. The rare allele T54 of the functional 
FABP2 Ala54Thr polymorphism is associated risk parameters of insulin resistance 
(Baier et al., 1996; Weiss et al., 2002). More recently, FABP2 promoter 
polymorphisms -80Del>T, -136Ins>Del (AGTAG>Del), -168AAG>T, -260C>G, -
471G>A, and -778G>T were identified. They are in complete linkage disequilibrium. 
The resulting FABP2 promoter haplotypes A>B were found to be associated with 
postprandial triglyceride levels (Geschonke et al., 2002), BMI (Damcott et al., 2003) 
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and type 2 diabetes (Li et al., 2006). Reporter analysis with FABP2 promoter 
constructs demonstrated that the two promoter haplotypes differ in their 
transcriptional activity by factor of two to three. Male FABP2 knock-out mice showed 
increased insulin and triglyceride plasma levels, increased body weight, and changes 
in liver histology, maybe resulting from impaired lipid metabolism (Agellon et al., 
2006; Vassileva et al., 2000). Thus, the expression level of FABP2 turns out to be an 
important determinant for insulin sensitivity and triglyceride metabolism. 
 
The regulation of FABP2 has been studied in some extent with other mammalian 
promoters, e.g. rat and mouse. In these studies, a direct involvement of HNF-4, ARP-
1 (Rottman and Gordon, 1993) and GATA-4/TGFβ-SMAD signaling (Belaguli et al., 
2007) in the transcriptional regulation of FABP2 was shown. Recently, we have 
demonstrated that the human FABP2 is regulated by the hepatocyte nuclear factor 
HNF-4 (Klapper et al., 2007), an endodermal transcription factor that binds fatty acids 
as ligands. As well as HNF-4, HNF-1α is also a key regulator of gene expression in 
pancreatic beta-cells, intestine, kidney, and liver. HNF-1α is abundantly expressed in 
enterocytes and bind as homo- or heterodimers with HNF-1β to the same consensus 
site (Rey-Campos et al., 1991). Heterozygous mutations in HNF-1α cause maturity-
onset diabetes of the young (MODY) type 3, which is the most prevalent MODY 
subtype (Yamagata et al., 1996). It is characterized by pancreatic beta-cell-deficient 
insulin secretion. Furthermore, HNF-1α is required for expression of specific intestinal 
genes during development (Bosse et al., 2007). It activates intestine-specific 
expressed genes such as sucrose isomaltase (SI) (Wu et al., 1994) and lactase-
phlorizin hydrolase (LPH) (Mitchelmore et al., 1998). Interaction of HNF-1α with other 
semi-restricted transcription factors such as in intestine abundantly expressed CDX-2 
and GATA-4 have been already described and are responsible for tissue-specific 
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high expression of intestinal genes (Boudreau et al., 2002; Divine et al., 2004; 
Krasinski et al., 2001; Mitchelmore et al., 2000; van Wering et al., 2004; van Wering 
et al., 2002). 
 
In the present study we aimed to investigate if the human FABP2 promoter and its 
variants are regulated by endodermal HNF-1α. By use of electromobility shift and 
super shift assays, reporter analysis, promoter mutants and cotransfection 
experiments we provide evidence that HNF-1α plays a major role in the control of the 
human FABP2 expression in the small intestine. 
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Materials and methods 
 
Cell culture. Hela cells and Caco-2 were purchased by German National Resource 
Centre for Biological Material (DSMZ, Braunschweig, Germany) and American Type 
Culture Collection (ATCC, Rockville, MD), respectively. Cells were maintained in 
MEM (Invitrogen, Carlsbad, CA), supplemented with 10% (Hela) and 20% fetal calf 
serum (Caco-2) (Invitrogen) and 1 mM non-essential amino acids (PAA, Cölbe, 
Germany) in a humidified incubator at 37°C under an atmosphere of 5% CO2. Cells 
were passaged at preconfluent densities by use of 0.05% trypsin/0.02% EDTA 
solution (Biochrom AG, Berlin, Germany) every 2-3 days.  
 
Human FABP2 promoter luciferase constructs. The dual luciferase system was used 
(Promega, Madison, WI). Cloning procedures were performed using Gateway 
Technology (Invitrogen), described previously (Klapper et al., 2007; Li et al., 2006). 
836 bp fragments upstream from initiation codon of the FABP2 promoter haplotype A 
and B were subcloned into pGL4.10[luc2] resulting in final pGL4.10[luc2]-hFABP2 
(haplotype A, WT) and pGL4.10[luc2]-hFABP2-B (haplotype B, HT B) promoter 
reporter constructs, respectively. The empty pGL4.10[luc2] vector served as a 
negative control. Introduction of mutations into HNF-1α consensus sites of 
pGL4.10[luc2]-hFABP2 resulting in pGL4.10[luc2]-hFABP2-M1 (M1) pGL4.10[luc2]-
hFABP2-M2 (M2), pGL4.10[luc2]-hFABP2-M1/M2 (M1/M2) were performed using 
Quick ChangeTM in vitro mutagenesis Kit (Stratagene, La Jolla, CA). All primers 
were purchased from MWG Biotech AG (Ebersberg, Germany). Sequences of 
primers are available on request. Verification of constructs was performed by 
sequencing. 
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Expression plasmids. Expression vector pRc/CMV-HNF-1α was a kind gift from Dr. 
G. Ryffel (University of Essen, Germany). Open reading frame of HNF-1α was 
amplified by PCR and subcloned in expression vector pDest40 using Gateway 
technology.  
 
Transient transfections and reporter assays. Transient transfections were performed 
as described recently with FuGene6 (Roche, Basel, Switzerland) according to the 
manufacturer's instructions (Klapper et al., 2007). 1 x 104 Caco cells or 4 x 103 Hela 
cells were plated per 96-well. Caco-2 cells were co-transfected with 47,5 ng 
pGL4.10[luc2]-hFABP2, pGL4.10[luc2]-hFABP2-M1 (M1), pGL4.10[luc2]-hFABP2-M2 
(M2), pGL4.10[luc2]-hFABP2-M1/M2 (M1/M2) or pGL4.10[luc2] as negative control 
and 2,5 ng pGL4.74[hRluc/TK] vector encoding Renilla luciferase as internal control. 
For co-transfections with HNF-1α in Caco-2 and Hela cells 30 ng of pGL4.10[luc2]-
hFABP2 promoter constructs and 66 ng of the expression vector pDest40-HNF-1α or 
66 ng empty pDest40 vector and 3 ng pGL4.74[hRluc/TK] vector were used. 
Luciferase activities were measured at indicated time points by Dual-Luciferase® 
Reporter Assay System (Promega). 
For preparation of nuclear extracts containing HNF-1α Hela cells were used. 4 x 105 
cells were seeded in T25 flasks, transfected with 4 µg expression plasmid pDest40- 
HNF-1α or empty expression vector pDest40 and extracts were prepared 48 h after 
transfection. 
 
Electromobility shift assay (EMSA). The Electromobility shift assay were essentially 
performed as described previously (Klapper et al., 2007). In supershift reactions the 
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following antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were used:  HNF-
1α(C-19): sc-6547 and HNF-1β (C-20): sc-7411. 
 
Statistical analyses. Statistical analyses were performed in GraphPad Prism 4 
(Graphpad Software, Inc., San Diego, CA) using ANOVA and unpaired two-tailed t-
test. Significant differences were considered for P values less than 0.05. 
 
Database identifier for investigated polymorphisms. For mentioned  polymorphisms of 
human FABP2 promoter haplotypes A and B the rs-numbers are: -80Del>T: 
rs5861422; -136AGTAG>Del: rs5861423; -168AAG>T: rs1973598; -260G/A: 
rs6857641; -471G/A:  rs2282688; -778G/T:  rs10034579. 
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Results 
 
HNF-1α activates FABP2 promoter in Caco-2 and Hela cells 
In order to study transcriptional regulation of human FABP2 promoter by HNF-1α, we 
initially expressed HNF-1α together with a luciferase reporter construct contained a 
functional 836 bp segment of the FABP2 promoter (Klapper et al., 2007) in intestinal 
Caco-2 cells. We measured reporter activities at different time points after transient 
transfection (24-120 h) by dual luciferase assay. As shown in figure 1, FABP2 
promoter reporter activity was increased up to 3.5-fold by HNF-1α compared to non-
HNF-1α transfected cells. Since Caco-2 cells express endogenously HNF-1α 
(Boudreau et al., 2001; Hu and Perlmutter, 1999), we additionally studied the 
activation of FABP2 promoter by HNF-1α in Hela cells that do express neither HNF-
1α (Hu and Perlmutter, 1999) nor FABP2 (Rottman and Gordon, 1993). The FABP2 
promoter activity was induced 20-fold by HNF-1α in Hela cells (Fig. 3A), compared to 
relative low activation in Caco-2 cells. These data indicate that HNF-1α is a strong 
activator of FABP2 expression. 
 
EMSA confirms specific interaction of HNF-1α with FABP2 promoter regions -185 to -
165 and -169 to -149 
To identify potential HNF-1α binding sites within the FABP2 promoter we performed 
in-silico search using TRANSFAC Professional database (Kel et al., 2003; Matys et 
al., 2006). Hereby, two potential HNF-1α binding sites within the promoter regions -
185 to -165 and -169 to -149 were found. These elements are of interest because 
their overlapping nature suggested strong interaction with HNF-1α. To test this 
hypothesis, we performed electromobility shift and super shift assays with a 49 bp 
oligonucleotide containing the two elements of the FABP2 promoter (Fig 2A). As 
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shown in figure 2B, we obtained two specific complexes (indicated as A and B) with 
nuclear protein extracts from post-confluent and differentiated Caco-2 cells (lane 1, 
2). Addition of an HNF-1α antibody abolished the specific shift A completely (lane 3), 
whereas an antibody against HNF-1β lead not to retardation of the specific 
complexes A or B (lane 4). Next, we used nuclear extracts from Hela cells that were 
transfected with HNF-1α. As shown in figure 2B, we could detect strong binding of 
HNF-1α (lane 7) to the oligonucleotide that were supershifted by addition of an HNF-
1α antibody (lane 8). No HNF-1α-DNA complexes and supershifted signals were 
formed with Hela extracts that were transfected with empty vector (lanes 5, 6).  
 
To investigate the specificity and binding characteristics of the two HNF-1α binding 
sites we performed EMSAs as competition experiments with nuclear protein extract 
from Caco-2 cells. As shown in figure 2C, the shifts A and B (lane 2) were competed-
away by 100 molar excess of unlabelled probe (lane 3). In contrast, an excess of an 
unrelated oligonucleotide (lane 4) could not interfere with binding of proteins. Next, 
we performed competition experiments with oligonucleotides (Fig. 2A) containing a 4-
bp mutation ATTA→CGGC in either of the binding sites -185 to -165 (M1) and -169 
to -149 (M2), or in both sites simultaneously (M1/M2). As shown in figure 2 C, excess 
of unlabelled M1 (lane 5) or M2 (lane 6) eliminated the shifts A and B partially 
indicating that HNF-1α is still able to bind the mutated unlabelled oligonucleotides. 
When both HNF-1α consensus sites were mutated simultaneously, the appropriate 
oligonucleotide M1/M2 did not bind any transcription factor and the specific shifts A 
and B were restored completely (lane 7). These data demonstrate that HNF-1α binds 
to both consensus sites within the FABP2 promoter regions -185 to -165 and -169 to 
-149. However, as evidenced by the supershift data (Fig. 2 B) only complex A is 
caused by HNF-1α binding.  
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The HNF-1α binding sites within FABP2 promoter region -185 to -165 and -169 to -
149 are responsible for 50 % of the FABP2 promoter activity 
To investigate the functional importance of HNF-1α binding sites at promoter regions 
-185 to -165 and -169 to -149 for FABP2 expression, promoter-reporter assays were 
performed in Caco-2 cells. Within the FABP2 promoter construct, we introduced a 4-
bp mutation ATTA → CGGC into the core sequences of either HNF-1α consensus 
sites (Fig. 2A) at positions -185 to -165 (M1), -169 to -149 (M2) or into both 
consensus sites simultaneously (M1/M2). We measured luciferase activities at 120 h 
after transfection because FABP2 mRNA as well as protein are considerably 
expressed in Caco-2 cells under these conditions (Li et al., 2006). As shown in figure 
3A, the mutation in HNF-1α binding site at position -185 to -165 (M1) decreases the 
relative reporter activity to 50% in comparison to the FABP2 promoter wild type 
construct. In contrast, mutation of HNF-1α binding site at position -169 to -149 (M2) 
had only marginal effect onto FABP2 promoter activity. Simultaneous disruption of 
both HNF-1α binding elements could not further reduce the promoter activity of 
FABP2 promoter mutant M1/M2 in comparison to single mutant M1. 
 
EMSA data showed two shifts with a HNF-1α binding sites containing oligonucleotide 
and nuclear protein extracts from Caco-2 cells. Thus, we cannot completely rule out 
that abolishing of binding of other transcription factors to these consensus sites may 
also be responsible for reduction of FABP2 promoter mutants in Caco-2 cells. For 
this reason we compared the activation of FABP2 promoter wild type and mutants by 
HNF-1α in Hela cells after transfection with a HNF-1α plasmid. As shown in figure 
3B, mutation of the HNF-1α binding site at position -185 to -165 lead to about 35% 
reduction of the HNF-1α induced FABP2 promoter-reporter activity. Mutation of the 
other HNF-1α element has essentially no effect. Disruption of both sites resulted in 
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nearly 50% decrease of HNF-1α mediated activation of FABP2 promoter mutant 
M1/M2. The results obtained in Hela cells are consistent with those obtained in post-
confluent Caco-2 cells, where only eliminating of HNF-1α element within FABP2 
promoter region -185 to -165 had significant influence onto basal activity of promoter 
constructs. In both cell lines elimination of both HNF-1α consensus sites results in 
about 50% reduction of FABP2 promoter basal activity and HNF-1α induced activity, 
respectively.  
 
The polymorphism -168AAG>T has no impact onto the activation of the FABP2 
promoter by HNF-1α 
Because FABP2 is a susceptibility gene for diabetes type 2 and related traits, its 
variant specific transcriptional regulation is of special interest. Two FABP2 promoter 
haplotypes which contain polymorphic sites as positions -80, -136, -168, -260, -471, 
and -778 were identified. As described previously by us and other groups, the 
resulting minor FABP2 promoter haplotype B has 2-3 fold lower basal transcriptional 
activity than major haplotype A in Caco-2 cells (Damcott et al., 2003; Formanack and 
Baier, 2004; Geschonke et al., 2002; Li et al., 2006). Interestingly, the two 
investigated HNF-1α binding sites harbour the polymorphic site -168AAG>T 
(rs1973598) within their matrices (Fig. 2A). Therefore we questioned if this 
polymorphic site influences the activation of FABP2 promoter by HNF-1α. As shown 
in Fig. 3B, there is no difference in HNF-1α induced activation of FABP2 promoter 
haplotype A (WT) and B. Accordingly, EMSAs revealed no difference in HNF-1α 
binding between the two haplotypes (not shown). Therefore, the FABP2 promoter 
polymorphism -168AAG>T has no impact onto the HNF-1α mediated transcriptional 
regulation of FABP2. 
  
 - 13 - 
Discussion 
In the present study we have investigated the presence of HNF-1α binding sites in 
the human FABP2 promoter. By using electromobility shift and super shift assays we 
identified two overlapping HNF-1α elements within FABP2 promoter regions -185 to -
165 and -169 to -149. Inactivation of -185 to -165 HNF-1α site resulted in reduction of 
basal and HNF-1α induced FABP2 promoter activity of about 50%. The disruption of -
169 to -149 site had only marginal effect. Mutation of both elements simultaneously 
decreased basal and HNF-1α induced promoter activity to 50% of wildtype activity in 
Caco-2 and Hela cells. Together, these data emphasize the crucial role of HNF-1α as 
activator of FABP2 promoter activity mediating the effect predominantly by binding to 
the more distal consensus site within FABP2 promoter region -185 to -165. 
Interestingly this binding site has no corresponding element in FABP2 mouse, rat or 
bovine promoter sequence at similar position but is conserved within a nearly 
conserved region in primates. This suggests a unique intestinal regulation of FABP2 
by HNF-1α in primates. 
 
Studies regarding transcriptional regulation of human FABP2 were mainly done to 
characterize the basal activities of the two FABP2 promoter haplotypes (Damcott et 
al., 2003; Formanack and Baier, 2004; Geschonke et al., 2002; Li et al., 2006). More 
recently, we have shown that FABP2 is regulated by HNF-4α (Klapper et al., 2007) 
and GATA factors (unpublished data), that are key regulators of intestinal 
differentiation processes. As described on liver and intestinal expressed fatty acid 
binding protein FABP1, LPH and SI promoters, HNF-1α co-operates with these 
factors (Boudreau et al., 2002; Divine et al., 2004; Krasinski et al., 2001; Rowley et 
al., 2006; van Wering et al., 2004; van Wering et al., 2002) and is also involved in 
developmental expression of intestinal genes (Bosse et al., 2007). Therefore, HNF-
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1α may be the third important regulator for expression of intestinal FABP2 during 
development and intestinal differentiation so far identified. 
 
An influence of dietary factors on HNF-1α and HNF-4α by modulating signalling 
pathways was provided by several observations and mechanisms. Firstly, HNF-1α is 
involved in the glucose-dependent transcriptional regulation of the sucrose-
isomaltase (Gu et al., 2007; Rodolosse et al., 1998; Rodolosse et al., 1996) and 
sodium-dependent glucose transporter (Vayro et al., 2001). Secondly, expression 
and DNA binding of HNF-1α in livers of protein restricted rats were increased (Marten 
et al., 1996). Thirdly, glucose as well fatty acids stimulated insulin secretion resulting 
in decreased activity of cAMP-dependent protein kinase A (PKA). Phosphorylation of 
HNF-4α by PKA results in decreased binding affinity to DNA (Viollet et al., 1997). 
Fourthly, an increased ATP level, that reflect the energy status of a cell, inhibit 5´-
AMP dependent kinase (AMPK) (Hardie, 2003). AMPK was shown to suppress the 
expression of several transcription factors including HNF-1α and HNF-4α (Leclerc et 
al., 2001) and phosphorylates HNF-4α which leads to reduced protein stability and 
dimer formation/DNA binding (Hong et al., 2003). Expression and stability of HNF-1α 
and binding of HNF-1β to DNA, as previously shown with sucrose-isomaltase 
promoter, is also dependent on protein phospatase 1a/2a activity (Carriere et al., 
2001). Together, diet induced changes in ratio of cellular protein kinase and 
phosphatase activity seem to regulate transcription factor activities, including HNFs. 
Therefore, HNF-1α may be a general mediator of nutritional signals and energy 
status for transcriptional adaptations of FABP2 expression in enterocytes. Based on 
this hypothesis it seems to be interesting to study the influence of FABP2 promoter 
haplotypes with respect to nutrients, such as fat intake in an epidemiological 
approach. 
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Interestingly, as well as FABP2 also HNF-1α is discussed to be associated with late 
onset form of diabetes type 2 (Holmkvist et al., 2006; Rissanen et al., 2000; Winckler 
et al., 2005). The identified coding SNPs of HNF-1α I27L and A98V alter its 
transcriptional activity (Holmkvist et al., 2006). Although there is no differential 
regulation of FABP2 promoter haplotypes by HNF-1α, the combination of particular 
FABP2 and HNF-1α genotypes in individuals may be of importance for differences in 
expression level of FABP2 in-vivo. It should be also noted, that there is no evidence 
in-vivo for genotype specific expression and function of FABP2 promoter haplotypes, 
since it is very difficult to obtain healthy probes from the intestine. Therefore it seems 
worthwhile to determine the relative importance of these HNF-1α genotypes on 
FABP2 expression level ex-vivo in future studies. 
 
In conclusion, in the present study we demonstrated that HNF-1α is a strong activator 
of human FABP2 promoter. This activation is essentially mediated by the FABP2 
promoter region -185 to -165. In future studies, the involvement of HNF-1α in 
differentiation and nutrition dependent regulation of FABP2 should be considered. 
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Figure legends 
 
Figure 1. HNF-1α induced activity of human FABP2 promoter construct was 
assessed in Caco-2 cells 24h, 48h, 72h, 96h or 120h after transfection using dual 
luciferase assay. The Firefly luciferase activities were normalized to Renilla luciferase 
activities and activities of negative control plasmid were subtracted. Resulting relative 
luciferase activities are expressed as fold activation of basal FABP2 promoter 
activities. Experiment was performed in triplicate for each sample. The results are 
expressed as mean ± SD.  
 
Figure 2. Specific binding of HNF-1α to human FABP2 promoter regions -185 to -165 
and -169 to -149. A, Sequences of oligonucleotides used in EMSA are presented. 
Underlined and bold nucleotides indicate the matrices and core sequence, 
respectively, of putative HNF-1α binding sites. Polymorphism -168 AAG>T is marked. 
Sequence is given in 5´→3´ direction. Sequence numbering is indicated relative to 
translational start site. B, EMSAs were performed with biotinylated oligonucleotide 
(WT) and without (lane 1) or with nuclear extracts from postconfluent Caco-2 cells (2-
4) or Hela cells (5-8), which were transfected with control plasmid (5, 6) or HNF-1α  
plasmid (7, 8). Supershifts were performed with antibodies against HNF-1α (3, 6, 8) 
or HNF-1β (4). Specific shifts (A, B) are indicated with an arrowhead. Supershift was 
indicated with an asterisk. C, EMSAs were performed with biotinylated 
oligonucleotide (WT) and without (lane 1) or with of nuclear extracts from 
postconfluent Caco2 cells (2-7). Competition experiments were carried with 100-fold 
excess of unlabelled oligonucleotides as indicated and described in A. Specific shifts 
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Figure 3. Reporter activity of human FABP2 promoter wild type (WT) and mutants 
(M1, M2, M1/M2) was assessed in Caco-2 cells (A) and in HNF-1α transfected Hela 
cells (B) using dual luciferase assay. A 4-bp mutation ATTA→CGGC was introduced 
into the core sequences of either HNF-1α consensus sites within FABP2 promoter 
regions -185 to -165 (M1), -169 to -149 (M2) or into both consensus sites 
simultaneously (M1/M2). Constructs M1, M2 and M1/M2 contain mutations that are 
shown in Fig. 1. The Firefly luciferase activities were normalized to Renilla luciferase 
activities and negative control was subtracted. Results are given as relative luciferase 
activities. Each experiment was performed in triplicate for each sample. The results 
are expressed as mean ± SEM for at least three independent experiments. A, Basal 
FABP2 promoter activities were determined in Caco-2 cells 120 after transfection. 
The relative reporter activity of FABP2 promoter WT was set to 100%. ***, p<0.001 
as compared with basal FABP2 promoter activity B, Induction of FABP2 promoter 
activity of promoter constructs by HNF-1α was assessed in Hela cells 48 h after 
transfection. The relative reporter activity obtained in Hela cells transfected with a 
control plasmid was set to 1-fold. HT B, FABP2 promoter haplotype B. In comparison 
to the wild type FABP2 promoter construct (= WT, haplotype A), HT B contains the 
minor allele of polymorphism -168AAG>T. **, p<0.01, ***, p<0.001 as compared with 
HNF-1α induced FABP2 promoter activity. 
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